

# *Klebsiella pneumoniae* carbapenemase variants: the new threat to global public health

Li Ding,<sup>1,2</sup> Siquan Shen,<sup>1,2</sup> Jing Chen,<sup>3</sup> Zhen Tian,<sup>3</sup> Qingyu Shi,<sup>1,2</sup> Renru Han,<sup>1,2</sup> Yan Guo,<sup>1,2</sup> Fupin Hu<sup>1,2</sup>

**AUTHOR AFFILIATIONS** See affiliation list on p. 19.

SUMMARY .....	1
INTRODUCTION.....	2
EFFICACY OF CEFTAZIDIME-AVIBACTAM IN THE TREATMENT INFECTIONS CAUSED BY KPC-PRODUCING <i>ENTEROBACTERALES</i> .....	3
EPIDEMIOLOGICAL CHARACTERISTICS OF KPC-TYPE CARBAPENEMASE.....	3
THE CLINICAL CHARACTERISTICS AND RISK FACTORS OF <i>bla</i> <sub>KPC</sub> VARIANTS.....	6
GENETIC SEQUENCES SURROUNDING <i>bla</i> <sub>KPC</sub> CARBAPENEMASE GENES.....	11
SUSCEPTIBILITY PROFILE OF THE STRAINS PRODUCING KPC VARIANTS.....	12
KPC VARIANTS POSE NEW CHALLENGES FOR LABORATORY TESTING.....	12
CURRENTLY AVAILABLE TREATMENT OPTIONS.....	16
Carbapenems.....	16
New β-lactam-β-lactamase inhibitor combinations.....	17
Meropenem-vaborbactam.....	17
Imipenem-relebactam.....	17
Aztreonam-avibactam.....	18
Other antimicrobial agents.....	18
Tigecycline.....	18
Polymyxin.....	18
FUTURE OUTLOOK.....	19
ACKNOWLEDGMENTS.....	19
AUTHOR AFFILIATIONS.....	19
FUNDING.....	20
REFERENCES.....	20
AUTHOR BIOS.....	25

**SUMMARY** *Klebsiella pneumoniae* carbapenemase (KPC) variants, which refer to the substitution, insertion, or deletion of amino acid sequence compared to wild *bla*<sub>KPC</sub> type, have reduced utility of ceftazidime-avibactam (CZA), a pioneer antimicrobial agent in treating carbapenem-resistant *Enterobacteriales* infections. So far, more than 150 *bla*<sub>KPC</sub> variants have been reported worldwide, and most of the new variants were discovered in the past 3 years, which calls for public alarm. The KPC variant protein enhances the affinity to ceftazidime and weakens the affinity to avibactam by changing the KPC structure, thereby mediating bacterial resistance to CZA. At present, there are still no guidelines or expert consensus to make recommendations for the diagnosis and treatment of infections caused by KPC variants. In addition, meropenem-vaborbactam, imipenem-relebactam, and other new β-lactam-β-lactamase inhibitor combinations have little discussion on KPC variants. This review aims to discuss the clinical characteristics, risk factors, epidemiological characteristics, antimicrobial susceptibility profiles, methods for detecting *bla*<sub>KPC</sub> variants, treatment options, and future perspectives of *bla*<sub>KPC</sub> variants worldwide to alert this new great public health threat.

**KEYWORDS** *bla*<sub>KPC</sub> variants, *Klebsiella pneumoniae*, ceftazidime-avibactam

**Editor** Jennifer Dien Bard, Children's Hospital Los Angeles, Los Angeles, California, USA

Address correspondence to Yan Guo, guoyan@fudan.edu.cn, or Fupin Hu, hufupin@fudan.edu.cn.

Li Ding and Siquan Shen contributed equally to this article. Author order was determined by the corresponding author after negotiation.

The authors declare no conflict of interest.

See the funding table on p. 20.

**Published** 8 November 2023

Copyright © 2023 American Society for Microbiology. All Rights Reserved.

## INTRODUCTION

Antimicrobial resistance has become one of the most severe threats to global public health. Infections caused by carbapenem-resistant *Enterobacterales* (CRE) are associated with a particularly significant economic burden and mortality rate (1), which is often two to three times higher than carbapenem-susceptible *Enterobacterales* (2). Furthermore, CRE isolates are resistant to most of the antimicrobial agents available, limiting the choice of antimicrobial agents in clinical practice (2–4). In 2017, the World Health Organization published a priority list of antibiotic-resistant bacteria that listed CRE, carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), and carbapenem-resistant *Acinetobacter baumannii* (CRAB) as the most urgent threats, suggesting that there is an urgent need to develop new antimicrobial agents to counteract the rapid acquisition of antimicrobial resistance (5).

The most important mechanism underlying carbapenem resistance in carbapenem-resistant *Klebsiella pneumoniae* (CRKP) and carbapenem-resistant *Escherichia coli* is the production of carbapenemases, including class A carbapenemases [mainly *Klebsiella pneumoniae* carbapenemase (KPC)], class B metallo- $\beta$ -lactamases [mainly New Delhi metallo- $\beta$ -lactamase (NDM)], and some class D OXA-48-like carbapenemases (mainly OXA-181, OXA-232, and OXA-163) (6). Based on those, novel  $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations were developed continually to cope with infections caused by carbapenemase-producing *Enterobacterales*, including ceftazidime-avibactam (CZA), meropenem-vaborbactam, and imipenem-relebactam. CZA, launched in the USA in 2015 and in China in 2019, displayed potent *in vitro* activity against KPC-producing *Enterobacterales* and is a pioneer antimicrobial agent in treating infections caused by KPC-producing *Enterobacterales* (7–9). Unlike traditional enzyme inhibitors such as tazobactam and sulbactam, avibactam does not contain a  $\beta$ -lactam structure. Avibactam acts by covalent acylation of its  $\beta$ -lactamase targets in a reversible process in which the structure of avibactam is restored by deacylation (without hydrolysis), and intact avibactam is released to provide long-lasting enzyme inhibition effect (10). Most importantly, avibactam has a broader spectrum, inhibiting class A carbapenemases (particularly KPC-2), extended-spectrum  $\beta$ -lactamases (ESBLs), class C cephalosporinases, and some class D carbapenemases. Therefore, since its introduction into clinical use, CZA has been considered one of the most effective antimicrobial agents for the treatment of infections caused by KPC-producing strains, especially *K. pneumoniae* (9).

Nevertheless, the widespread clinical use of CZA has forced CRE to mutate to adapt to the increasing antibiotic pressure. The *bla*<sub>KPC</sub> variant derived from *bla*<sub>KPC-2</sub> or *bla*<sub>KPC-3</sub> mutation has been reported (11–13). The *bla*<sub>KPC</sub> variant usually refers to the substitution, insertion, or deletion of one or more amino acids compared to wild *bla*<sub>KPC</sub> type (such as *bla*<sub>KPC-2</sub> and *bla*<sub>KPC-3</sub>), and those leading to modifications in the amino acid sequence with the carbapenemase active site, which are of greatest concern. So far, more than 145 *bla*<sub>KPC</sub> variants have been reported worldwide, and most of the new variants were discovered in the past 3 years. A crucial phenotypic feature of KPC variants is their resistance to CZA compared to the wild-type (WT) gene product that is notably susceptible. This has led to new challenges in appropriate therapeutic selection (11, 14). In addition to posing a challenge for antimicrobial therapy, *bla*<sub>KPC</sub> variants may challenge the performance of some classical carbapenemase detection methods used by clinical laboratories (14).

This review aims to discuss the clinical characteristics, risk factors, epidemiological characteristics, antimicrobial susceptibility profiles, methods for detecting *bla*<sub>KPC</sub> variants, treatment options, and future perspectives of *bla*<sub>KPC</sub> variants worldwide to alert this new significant public health threat.

## EFFICACY OF CEFTAZIDIME-AVIBACTAM IN THE TREATMENT INFECTIONS CAUSED BY KPC-PRODUCING *ENTEROBACTERALES*

A multicenter, prospective, observational study was conducted between January 2018 and March 2019 to evaluate the outcomes and predictors of mortality in patients with KPC- or OXA-48-*K. pneumoniae* infections treated with CZA, with a focus on KPC-*K. pneumoniae* bloodstream infections (BSIs) (15). The study included 147 patients, 140 isolates were KPC-positive and 7 isolates were OXA-48-positive. Of these patients, 68 (46.3%) received CZA and 79 (53.7%) received CZA in combination with at least one other active agent, such as colistin, aminoglycosides, colistin plus tigecycline, tigecycline, trimethoprim/sulfamethoxazole, fosfomycin, etc. The 14- and 28-day mortality rates were 9% and 20%, respectively. The clinical characteristics of 71 patients with KPC-*K. pneumoniae* BSIs treated with a regimen containing CZA (cases) and of 71 patients, matched by propensity score, whose KPC-*K. pneumoniae* BSIs were treated with regimens not containing ceftazidime/avibactam (controls) were collected in this study. The results showed that 28-day mortality in the patients with KPC-*K. pneumoniae* BSIs treated with CZA was significantly lower than that observed in the matched patients whose KPC-*K. pneumoniae* BSIs were treated with regimens without CZA (18.3% vs 40.8%;  $P = 0.005$ ). A retrospective, observational, multicenter study of 577 adults with BSIs or non-bacteremic infections primarily involving the urinary tract, lower respiratory tract, and intra-abdominal structures was conducted to evaluate the outcomes and mortality in patients with KPC-*K. pneumoniae* infections treated with CZA monotherapy and CZA combination regimens (16). The results showed that the 30-day all-cause mortality rate was 25% (146/577). There was no significant difference in mortality between patients treated with CZA alone and those treated with combination regimens (26.1% vs 25.0%,  $P = 0.79$ ). Another retrospective multicenter study of 138 Italian patients with KPC-*K. pneumoniae* infections (KPC-*K. pneumoniae* bacteremic, KPC-*K. pneumoniae* non-bacteremic), all of whom received CZA as salvage therapy, was conducted to document the clinical characteristics and outcomes of these cases and to specifically investigate the outcomes and predictors of mortality in patients with KPC-*K. pneumoniae* bacteremia (17). All KPC-*K. pneumoniae* isolates were susceptible to CZA *in vitro*. The overall 30-day mortality rate was 34.1% (47/138), and 8.7% (12/138) of patients experienced recurrent KPC-*K. pneumoniae* infection after discontinuation of CZA treatment. In addition, the 30-day mortality rate of 109 patients with KPC-*K. pneumoniae* bacteremia receiving CZA was significantly lower than that of the control group (36.5% vs 55.7%,  $P = 0.005$ ). This suggests that CZA-based therapy is an effective treatment option for infections caused by KPC-producing Gram-negative bacteria.

In the context of increasing carbapenem resistance in *Enterobacteriales*, the introduction of CZA, with its broad spectrum of enzyme inhibition and low side effects, has provided a major boost to the clinical treatment of CRE infections (7, 9). CZA is the preferred treatment option for KPC-producing infections outside of the urinary tract (18). However, as CZA becomes more widely used in clinical practice, KPC-producing strains develop resistance to CZA through mutation under conditions of antimicrobial pressure and the presence of various other factors, leading to treatment failure (19, 20).

## EPIDEMIOLOGICAL CHARACTERISTICS OF KPC-TYPE CARBAPENEMASE

First identified in 1996 in the northeastern United States, KPCs are the most common and widely distributed carbapenemases (21). KPCs can hydrolyze most  $\beta$ -lactams, including carbapenems, cephalosporins, monobactams, and cephamycins. They have been identified in many Gram-negative bacteria, including *Enterobacteriales* and nonfermenting bacteria (e.g., *P. aeruginosa* and *A. baumannii*). *K. pneumoniae* is the most predominant KPC-producing species (22, 23). The strains producing KPC-2 or KPC-3 showed diverse susceptibility to imipenem and meropenem but were usually resistant to ertapenem. With the widespread use of carbapenems, KPC-producing bacteria have spread internationally. The dissemination of *bla*<sub>KPC</sub> involves clonal spread, horizontal transfer, and plasmid-mediated spread. The prevalent *bla*<sub>KPC</sub> variants vary

with geographic location, e.g., a predominance of *bla*<sub>KPC-2</sub> in China but a predominance of *bla*<sub>KPC-3</sub> and *bla*<sub>KPC-2</sub> in the Americas and Europe (24–28). The international spread of KPC-producing *K. pneumoniae* is primarily associated with a single multilocus sequence type, sequence type 258 (ST258), and its variants (29). *K. pneumoniae* ST258 is the culprit in over 77% of KPC-producing *K. pneumoniae* infections in the USA and 90% in Israel (25, 26). The profile of sequence types (STs) was different between regions. ST512 is the most prevalent ST in Italy (28), whereas ST11 and ST437 predominate in China and Brazil, respectively (30, 31). Transmission of *bla*<sub>KPC</sub> genes is mainly mediated by horizontal transfer of plasmids or mobility of small genetic elements (mainly Tn4401 transposon) (32). The *bla*<sub>KPC</sub> in *K. pneumoniae* had been reported on various plasmid types, such as IncF, IncI2, IncX, IncA/C, IncR, and ColE1, but the predominant plasmid type is IncF with FII K replicon (29, 33, 34).

Sporadic variants of *bla*<sub>KPC</sub> were identified in 2006–2018 (≤7 reported per year) (35). However, since 2019, reports of *bla*<sub>KPC</sub> variants have increased dramatically. The number reported between 2019 and 2020 exceeds the sum of reported *bla*<sub>KPC</sub> variants in the previous 17 years (Fig. 1 and 2). The emergence of *bla*<sub>KPC-2</sub> or *bla*<sub>KPC-3</sub> mutants, such as *bla*<sub>KPC-33</sub>, *bla*<sub>KPC-31</sub>, etc., as the most prevalent cause of bacterial resistance to CZA during therapy has been attributed to the mechanism that altered the Ω-loop hydrogen






FIG 1 Distribution of *Klebsiella pneumoniae* carbapenemase variants based on KPC-2 and KPC-3 mutations. The data are calculated based on the number of *Klebsiella pneumoniae* carbapenemase variants uploaded to the National Center for Biotechnology Information each year in each region (<https://www.ncbi.nlm.nih.gov/>).



**FIG 2** KPC variants evolutionary tree analysis chart (A) and the number of new variants reported in PubMed over the years (B) (up to March 2023).

bonding structure of KPC (Fig. 3) (36, 37). Compared to the wild type, KPC variant protein presented reduced catalytic ability to carbapenems, meanwhile responding poorly to avibactam inhibition (38–40). The crystallographic analysis of the D179N KPC-2 variant and the D179Y variant revealed the depth mechanism of CZA resistance conferred by D179N/Y variants of KPC-2 (40). The D179N KPC-2 structure showed that the change of the carboxyl to an amide moiety at position 179 disrupted the salt bridge with R164 present in KPC-2. Additional interactions were disrupted in the Ω-loop, causing a decrease in the melting temperature. Shifts originating from N179 were also transmitted toward the active site, including ~1-Å shifts of the deacylation water and interacting residue N170 (40). The structure of the D179Y KPC-2 (KPC-33) revealed more drastic changes, as this variant exhibited disorder of the Ω-loop, with other flanking regions also being disordered (40). On the contrary, the crystal structure of D179N KPC-2 in complex with vaborbactam revealed wild-type KPC-2-like vaborbactam-active site interactions,





**FIG 3**  $\Omega$ -Loop destabilization as a mechanism of resistance to ceftazidime-avibactam. (A) Structure of KPC-2 (Protein Data Bank accession number [5UL8](#)),  $\Omega$ -Loop was shown in yellow; (B) hydrogen bonding network involving  $\Omega$ -loop Arg and Asp residues in the WT KPC-2 (40); (C) Hydrogen bonding network involving  $\Omega$ -loop Arg and Asp residues in D179N KPC-2 (40).

with D179N change in KPC-2 that does not perturb the binding mode of vaborbactam significantly (40).

By March 2023, 145 *bla*<sub>KPC</sub> variants are registered in the National Center for Biotechnology Information (NCBI) database, all derived from mutations of *bla*<sub>KPC-2</sub> or *bla*<sub>KPC-3</sub>. Overall, *bla*<sub>KPC-4</sub> ( $n = 26$ ), *bla*<sub>KPC-33</sub> ( $n = 9$ ), *bla*<sub>KPC-12</sub> ( $n = 8$ ), *bla*<sub>KPC-6</sub> ( $n = 5$ ), *bla*<sub>KPC-71</sub> ( $n = 4$ ), *bla*<sub>KPC-10</sub> ( $n = 3$ ), *bla*<sub>KPC-76</sub> ( $n = 3$ ), *bla*<sub>KPC-44</sub> ( $n = 3$ ), *bla*<sub>KPC-25</sub> ( $n = 2$ ), *bla*<sub>KPC-36</sub> ( $n = 2$ ), *bla*<sub>KPC-5</sub> ( $n = 2$ ), and *bla*<sub>KPC-90</sub> ( $n = 2$ ) were mutants from *bla*<sub>KPC-2</sub>. These KPC-2 variants were mainly identified from the USA ( $n = 35$ ), China ( $n = 20$ ), and Italy ( $n = 3$ ). In contrast, *bla*<sub>KPC-31</sub> ( $n = 8$ ), *bla*<sub>KPC-66</sub> ( $n = 4$ ), *bla*<sub>KPC-67</sub> ( $n = 3$ ), *bla*<sub>KPC-18</sub> ( $n = 2$ ), *bla*<sub>KPC-29</sub> ( $n = 2$ ), *bla*<sub>KPC-40</sub> ( $n = 2$ ), *bla*<sub>KPC-49</sub> ( $n = 2$ ), *bla*<sub>KPC-61</sub> ( $n = 2$ ), and *bla*<sub>KPC-70</sub> ( $n = 2$ ) were mutants from *bla*<sub>KPC-3</sub>. These *bla*<sub>KPC-3</sub> variants were mainly reported from Italy ( $n = 15$ ), the USA ( $n = 8$ ), and France ( $n = 1$ ). We aggregated the number of *bla*<sub>KPC</sub> variants uploaded to NCBI each year by region, and the global distribution of specific variants is shown in Fig. 1. The USA and China ranked first and second with 63 and 59 detected cases, respectively. It is worth noting that China showed a sudden increase in *bla*<sub>KPC</sub> variants in 2020 after ceftazidime-avibactam was approved for clinical use in 2019. The threat of *bla*<sub>KPC</sub> variants in China may be more worthy of vigilance. The *bla*<sub>KPC</sub> variants gene have been identified in various Gram-negative bacilli, including *K. pneumoniae* (73.8%), *Enterobacter hormaechei* (7.1%), *E. coli* (6%), and *Enterobacter cloacae* (5.5%), among which *K. pneumoniae* is predominant (Tables 1 and 2).

The most frequently reported *bla*<sub>KPC-2</sub> variant, *bla*<sub>KPC-33</sub>, was derived from *bla*<sub>KPC-2</sub> with a single amino acid substitution. It was first reported in Italy in October 2020 and subsequently reported in China and Greece (41, 42). In these studies, *bla*<sub>KPC-33</sub> was harbored by *K. pneumoniae*, which was predominantly isolated from rectal swabs and sputum samples. Although the ST distribution of KPC-33-producing *K. pneumoniae* varies in different regions, ST11 in China, ST1685 in Italy, and ST39 in Greece, these strains share the same feature that all *bla*<sub>KPC-33</sub> are carried by Tn4401-like transposons (30, 37, 42). The most frequently reported *bla*<sub>KPC-3</sub> variant, *bla*<sub>KPC-31</sub>, derived from *bla*<sub>KPC-3</sub> with a single amino acid substitution (D179Y), was first reported in Italy in August 2019 and subsequently mainly reported in Italy, France, and Spain (12, 36, 43–45). The *K. pneumoniae* strain producing *bla*<sub>KPC-31</sub> is primarily detected in blood specimens, and the corresponding STs included ST512, ST307, ST101, and ST2502. Like other *bla*<sub>KPC</sub> variants, all *bla*<sub>KPC-31</sub> are located on the genetic element of Tn4401-like transposons (12, 36, 43–45).

### THE CLINICAL CHARACTERISTICS AND RISK FACTORS OF *bla*<sub>KPC</sub> VARIANTS

In 2017, Shields et al. (46) first reported the evolution of *bla*<sub>KPC</sub> in three patients with infection due to KPC-producing *K. pneumoniae*, resulting in therapy failure. *bla*<sub>KPC-3</sub> was

TABLE 1 Distribution of KPC variants based on bla<sub>KPC-2</sub>

KPC-2-like enzyme	Country and year of first publication	Geographical distribution	Bacteria	Divergence from KPC-2	Plasmids	Clonal dissemination	Genetic environment	Accession number
KPC-4	USA, 2013	USA	<i>Enterobacter cancerogenus</i> , <i>Enterobacter cloacae</i> , <i>Serratia marcescens</i> , <i>K. pneumoniae</i>	P104R/V240G	IncL/M, IncN, IncH12	<i>K. pneumoniae</i> : ST258, ST834, ST964, ST307; <i>Enterobacter cloacae</i> : ST171	Tn4401 variants	JQ837276
KPC-5	USA, 2013	USA	<i>Pseudomonas aeruginosa</i> , <i>K. pneumoniae</i>	Pro103→Arg	IncX	<i>K. pneumoniae</i> : ST429	Tn5563 and IS6100A, Tn4401 variants	NG_049259
KPC-6	USA, 2012	USA	<i>K. pneumoniae</i>	Val240Gly			Tn4401 variants	EU555534
KPC-10	Puerto Rico, 2010	Puerto Rico	<i>Acinetobacter calcoaceticus-baumannii</i>	H272Y				GQ140348
KPC-12	China, 2021	China	<i>K. pneumoniae</i>	L169M	IncFII, IncR		Downstream of ISKpn6 of ISKpn6	CP036400
KPC-14	France, 2019	France, USA, Italy	<i>K. pneumoniae</i>	D242-GT-243 deletion	IncN	<i>K. pneumoniae</i> : ST16, ST1685	Tn4401b	CP045022
KPC-15	China, 2014	China	<i>K. pneumoniae</i>	119 Leucine and 146 lysine			ISKpn6-like transposon	KC433553
KPC-16	China, 2016	China	<i>K. pneumoniae</i>	P202S and F207L		<i>K. pneumoniae</i> : ST11		NG_049249
KPC-17	China, 2016	China	<i>K. pneumoniae</i>	F207L		<i>K. pneumoniae</i> : ST11		KC465200
KPC-21	Portugal, 2018	Portugal	<i>E. coli</i>	Trip105Arg		<i>E. coli</i> : ST131	Upstream a partial ISKpn6 and downstream a truncated Tn3 transposon	MH133192
KPC-24	Chile, 2016	Chile	<i>K. pneumoniae</i>	R6P		<i>K. pneumoniae</i> : ST1161	Tn4401a	KR052099
KPC-33	Italy, 2020	Italy, China, Greece	<i>K. pneumoniae</i>	D179Y	IncFH/R	<i>K. pneumoniae</i> : ST11, ST1685, ST39		MT550691
KPC-35	USA, 2019	USA	<i>K. pneumoniae</i>	L169P	IncF	<i>K. pneumoniae</i> : ST258		MH404098
KPC-35	China, 2019	China	<i>K. pneumoniae</i>	L169P		<i>K. pneumoniae</i> : ST11		CP050279.1
KPC-36	Italy, 2020	Italy	<i>K. pneumoniae</i>	D163E		<i>K. pneumoniae</i> : ST1519	Tn4401a	MK976712
KPC-44	Greece, 2021	Greece, Finland	<i>K. pneumoniae</i>	276ins YTRAPNKDDKH-SEAV	IncFIB	<i>K. pneumoniae</i> : ST39	Tn4401a	SAMN14734455
KPC-51	China, 2020	China	<i>K. pneumoniae</i>	D179N, Y241H, H274N				MN725731
KPC-52	China, 2020	China	<i>K. pneumoniae</i>	D179Y, valine insertion after 262 position				MN725732
KPC-55	South Korea, 2020	South Korea	<i>K. pneumoniae</i>	T794A	IncX3	<i>K. pneumoniae</i> : ST307	Tn4401a	MT028409
KPC-57	Greece, 2021	Greece	<i>K. pneumoniae</i>	D179V	IncFIB	<i>K. pneumoniae</i> : ST39	Tn4401a	MT358626
KPC-71	China, 2022	China	<i>K. pneumoniae</i>	Ser182dup	pKpQIL	<i>K. pneumoniae</i> : ST11	Tn4401a	OK315339
KPC-74	China, 2021	China	<i>K. pneumoniae</i>	G239_V240del	IncFH/R	<i>K. pneumoniae</i> : ST11	TnA51-ISKpn6-like-bla <sub>KPC-74</sub> -ISKpn27-TnA-IS26	NG_070742
KPC-82	USA, 2021	USA	<i>Citrobacter koseri</i>	Ala267-Ser275	IncN		Tn4401 variants	MW485086
KPC-90	China, 2021	China	<i>Pseudomonas aeruginosa</i>	180ins Tyr-Thr		<i>Pseudomonas aeruginosa</i> : ST463	IS26-ISKpn6-bla <sub>KPC-90</sub> -IS26	MZ570431

(Continued on next page)

TABLE 1 Distribution of KPC variants based on *bla*<sub>KPC-2</sub> (Continued)

KPC-2-like enzyme	Country and year of first publication	Geographical distribution	Bacteria	Divergence from KPC-2	Plasmids	Clonal dissemination	Genetic environment	Accession number
KPC-93	China, 2022	China	<i>K. pneumoniae</i>	267ins Pto-Asn-Arg- Ala	IncFII-R	<i>K. pneumoniae</i> : ST11	Tn1721-ΔIS <sub>Kpn6</sub> - <i>bla</i> <sub>KPC-93</sub> -IS <sub>Kpn8</sub> -IS26	MZ569034
KPC-112	China, 2022	China	<i>K. pneumoniae</i>	del166Leu/167Asn and 242Gly/243Thr	IncFII-R	<i>K. pneumoniae</i> : ST15	Tn1721-ΔIS <sub>Kpn6</sub> - <i>bla</i> <sub>KPC-112</sub> -IS <sub>Kpn8</sub> -IS26OM177660	
KPC-113	China, 2023	China	<i>Pseudomonas aeruginosa</i>	266ins Gly	Type I	<i>P. aeruginosa</i> : ST3903	IS6100-IS <sub>Kpn27</sub> - <i>bla</i> <sub>KPC-113</sub> - ΔIS <sub>Kpn6</sub> -Tn1403	OM317762
KPC-123	China, 2022	China	<i>Citrobacter koseri</i>	ins179_TY and ins270_DDKHSEA			IS <sub>Kpn27</sub> - <i>bla</i> <sub>KPC</sub> -IS <sub>Kpn6</sub>	ON012820



TABLE 2 Distribution of KPC variants based on bla<sub>KPC-3</sub>

KPC-3-like enzyme	Country and year of first publication	Geographical distribution	Bacteria	Divergence from KPC-3	Plasmids	Clonal dissemination	Genetic environment	Accession number
KPC-23	Greece, 2019	Greece	<i>K. pneumoniae</i>	V240A	IncFIIk-FIB	<i>K. pneumoniae</i> : ST258	Tn4401a	AWU66461
KPC-28	France, 2019	France	<i>E. coli</i>	Δ242-GT-243 and H274Y				KY282958
KPC-29	Italy, 2021	Italy	<i>K. pneumoniae</i>	D272insKDD	pKpQIL	<i>K. pneumoniae</i> : ST512		WP_096807439
KPC-31	Italy, 2019	Italy	<i>K. pneumoniae</i>	D179Y	FIA(H11)-R	<i>K. pneumoniae</i> : ST512, ST307, ST101, ST2502	Tn4401 variants	MAPH01000113
KPC-39	Italy, 2020	Italy, France	<i>K. pneumoniae</i>	A172T	FIA(H11)-R	<i>K. pneumoniae</i> : ST101		
KPC-40	USA, 2019	USA	<i>Enterobacter hormaechei</i>	L167_E168dup	IncN	<i>Enterobacter hormaechei</i> : ST407		WP_115470049
KPC-41	Switzerland, 2019	Switzerland,	<i>K. pneumoniae</i>	269-Pro-Asn-Lys-270	IncFII	<i>K. pneumoniae</i> : ST395		MK497255
KPC-48	Spain, 2020	Spain	<i>K. pneumoniae</i>	L169P-A172T				MN422013
KPC-49	Spain, 2021	Spain, Italy	<i>E. coli, K. pneumoniae</i>	Arg-163-Ser	IncF	<i>E. coli</i> : ST131, <i>K. pneumoniae</i> : ST512	Tn4401a	MN619655
KPC-50	Switzerland, 2020	Switzerland	<i>K. pneumoniae</i>	276-Glu-Ala-Val-277	IncFIB	<i>K. pneumoniae</i> : ST258		MN654342
KPC-94	Spain, 2022	Spain	<i>K. pneumoniae</i>	LN169-170H		<i>K. pneumoniae</i> : ST512		
KPC-95	Spain, 2022	Spain	<i>K. pneumoniae</i>	D179Y and A172T		<i>K. pneumoniae</i> : ST512		
KPC-115	Argentina, 2022	Argentina	<i>K. pneumoniae</i>	del168Leu/169Asn and Ser170Pro		<i>K. pneumoniae</i> : ST11	Tn4401a	OM714909
KPC-121	Italy, 2022	Italy	<i>K. pneumoniae</i>	179ins Ser		<i>K. pneumoniae</i> : ST512		SAMN27596901
KPC-125	Italy, 2022	Italy	<i>K. pneumoniae</i>	Asp179Ala		<i>K. pneumoniae</i> : ST512		ON012820

TABLE 3 Summary of KPC variant cases

No.	Sex/age, years	Infection	Organism	Wild-type KPC variant	ST	Therapy before the KPC variant was detected	Therapy	Outcome	Pathogen clearance	Reference
1	Male/59	Pneumonia	<i>K. pneumoniae</i>	KPC-3	ST2502	CZA, 10 d	Meropenem 2 g tid 3 h	Cure	No	(45)
2	Male/68	Bloodstream infection	<i>K. pneumoniae</i>	KPC-3	ST512	CZA, 14 d	Meropenem-vaborbactam 1/1 g q8	Cure	Yes	(44)
3	Male/40	Bloodstream infection, pneumonia	<i>K. pneumoniae</i>	KPC-3	ST307	Meropenem, tigecycline, polymyxin B, CZA	Meropenem + polymyxin B	Failure	No	(51)
4	Female/50+	Subphrenic abscess	<i>K. pneumoniae</i>	KPC-3	ST258	CZA, 19 d	Piperacillin/tazobactam, gentamicin	NA	No	(46)
5	Female/70+	Pneumonia	<i>K. pneumoniae</i>	KPC-3	ST258	CZA, 15 d	Meropenem + polymyxin B	Cure	Yes	(46)
6	Female/NA	Bloodstream infection, pneumonia	<i>K. pneumoniae</i>	KPC-3	ST11519	CZA, 14 d	Meropenem (increased dose, extended infusion time) + gentamicin	Failure	No	(50)
7	Female/60	Pneumonia, wound infection	<i>K. pneumoniae</i>	KPC-3	ST101	CZA, 14 d	CZA + tigecycline	Failure (death)	No	(48)
8	Male/47	Intra-abdominal infection	<i>K. pneumoniae</i>	KPC-3	NA	CZA, 12 d	Imipenem, tigecycline, gentamicin	Cure	No	(53)
9	Male/67	Bloodstream infection, pneumonia	<i>K. pneumoniae</i>	KPC-3	ST258	CZA, 15 d	Meropenem 1 g q12, 12 d	Cure	Yes	(52)
10	Female/40+	Pneumonia, urinary tract infection	<i>K. pneumoniae</i>	KPC-3	ST258	CZA, 14 d	Meropenem	Failure	No	(46)
11	Male/24	Bloodstream infection, pneumonia	<i>K. pneumoniae</i>	KPC-2	NA	CZA, 33 d	Polymyxin B + gentamicin + tigecycline, meropenem-vaborbactam 25 d	Cure	Yes	(49)
12	Male/42	Pneumonia	<i>K. pneumoniae</i>	KPC-2	ST11	CZA, 16 d	Imipenem + amoxicillin/clavulanate + polymyxin B	Failure	No	(11)
13	NA	Bloodstream infection	<i>K. pneumoniae</i>	KPC-2	ST39	CZA + tigecycline, 14 d	Colistin + trimethoprim/sulfamethoxazole	Cure	Yes	(47)
14	Female/40+	Bloodstream infection	<i>E. coli</i>	KPC-3	ST131	CZA, 10 d	Amikacin 500 mg/24 h i.v.	Cure	Yes	(54)
15	NA	Bloodstream infection	<i>Citrobacter koseri</i>	NA	NA	CZA, 28 d	Meropenem-vaborbactam	Cure	Yes	(56)
16	Male/22	Pneumonia	<i>K. pneumoniae</i>	KPC-2	ST11	CZA, 41 d	Imipenem + CZA	Cure	Yes	(57)
17	Female/52	Pneumonia	<i>K. pneumoniae</i>	KPC-2	ST11	CZA, 9 d	CZA + amikacin, meropenem + tigecycline + fosfomycin	Failure	No	(55)
18	Male/50	Pneumonia	<i>K. pneumoniae</i>	KPC-2	ST859	CZA, 9 d	CZA + tigecycline + fosfomycin + meropenem	Failure	No	(55)

mutated to *bla*<sub>KPC-31</sub> and *bla*<sub>KPC-32</sub> during CZA treatment for 10 to 19 days. By searching the PubMed database, up to August 2022, 18 cases of infections caused by KPC variant-producing *Enterobacterales* have been reported internationally. These infections were reported in 11 males, 5 females, and 2 patients of unknown sex. *K. pneumoniae* was the pathogen in 16 cases, *E. coli* and *C. koseri* in one case each (Table 3) (11, 44–55). Limited data showed that *bla*<sub>KPC-31</sub> (44.4%, 8/18) and ST 258 (22.2%, 4/18) were the dominant genotypes and ST type of *bla*<sub>KPC</sub> variants. All patients were treated with CZA (for 9–41 days) before KPC variant-producing *Enterobacterales* strains were identified, suggesting that CZA treatment may be an independent risk factor for inducing mutations of *bla*<sub>KPC</sub>. In the 18 patients infected with a KPC variant-producing CRE strain, the treatment failure rate was up to 38.9% (7/18), and 50% (8/16) of the patients were older than 50. Four patients continued to receive CZA in combination with other antimicrobial agents (including meropenem, tigecycline, amikacin, or imipenem) for anti-infective treatment after CZA-resistant *bla*<sub>KPC</sub> variant strains were identified. Among them, three patients were not successfully cured after receiving the above anti-infection regimens, while one was cured after receiving CZA in combination with imipenem. Eleven patients discontinued CZA therapy and were treated with other antimicrobial agents, to which the bacterial isolates were susceptible, including tigecycline, polymyxin B, colistin, meropenem, and amikacin. Among them, seven patients' infection symptoms were effectively controlled. Three patients were successfully treated with meropenem-vaborbactam, based on the bacteria being *in vitro* susceptible to meropenem-vaborbactam. However, more real-world research data are still needed to confirm the effectiveness of meropenem-vaborbactam in treating infection caused by the *bla*<sub>KPC</sub> variant.

A retrospective, observational research was conducted with all patients admitted to the intensive care unit (ICU) dedicated to coronavirus disease patients at the City of Health & Sciences in Turin, between May 2021 and January 2022, with the primary endpoint to study strains with resistance to CZA. This study enrolled 17 patients with colonization or invasive infection caused by CZA-resistant *K. pneumoniae* which were susceptible to meropenem. It is worth noting that 76.5% of patients did not receive therapy with CZA. Cluster analysis showed that 16 KPC-33-producing *K. pneumoniae* isolates belonged to a single clone, indicating that there was a risk of clonal transmission of this novel *bla*<sub>KPC</sub> variant (58).

KPC-2 or KPC-3 carbapenemase-producing *K. pneumoniae* are susceptible to mutations during treatment leading to treatment failure, and the occurrence of such mutations is not easily recognized clinically and may be missed, putting infected patients at high risk. Available studies suggest that the use of ceftazidime-avibactam is an important factor in the development of mutations in KPCase-producing *K. pneumoniae*. As there are no current guidelines for the treatment of infections caused by KPCase-producing mutants of *K. pneumoniae*, it is recommended that clinical monitoring for changes in antimicrobial susceptibility to antimicrobial agents, particularly carbapenems and ceftazidime-avibactam, be performed at regular intervals (e.g., 3–5 days) to monitor for the occurrence of mutations.

## GENETIC SEQUENCES SURROUNDING *bla*<sub>KPC</sub> CARBAPENEMASE GENES

Transposable elements play an essential role in bacteria's genetic variation and evolution. In most countries and regions, such as Europe (33), the USA (59), and Brazil (31, 60), the *bla*<sub>KPC</sub> is mainly located on transposable elements like Tn4401, Tn3-Tn4401 chimera CTB, and IS26. Tn4401 and Tn3-Tn4401 chimera CTB, belonging to the Tn3 family, can mobilize *bla*<sub>KPC-2</sub> at a high transposition frequency. Tn4401, a 10 kb transposon, has been reported as the genetic structure mediating original *bla*<sub>KPC</sub> acquisition, with the gene order of Tn4401-*tnpR*, Tn4401-*tnpA*, *ISKpn7*, *bla*<sub>KPC</sub>, and *ISKpn6* (61). Owing to the diversity in the intervening sequence between the *ISKpn7* and *bla*<sub>KPC</sub> genes, a total of eight unique Tn4401 isoforms (a to h) have been characterized, with Tn4401a and Tn4401b being the most widespread (62). In Asia, *bla*<sub>KPC-2</sub> is predominantly located on different variants of Tn1721 and IS26 (63–65). However, the structural sequences

surrounding the *bla*<sub>KPC</sub> variants genes are infrequently described. Scattered studies have shown that some KPC variants, similar to *bla*<sub>KPC-2</sub> and *bla*<sub>KPC-3</sub>, are located within the Tn4401 transposon (56). The core structure of ISKpn6-*bla*<sub>KPC</sub>-ISKpn28 was identified in *bla*<sub>KPC-12</sub> and *bla*<sub>KPC-74</sub> (Tables 1 and 2). Therefore, we collected 52 *bla*<sub>KPC</sub> variant gene sequences from NCBI databases to analyze the genetic environment surrounding the *bla*<sub>KPC</sub> gene. The result showed the core structure of the *tnpR-tnpA-ISKpn7-bla*<sub>KPC</sub>-ISKpn6 was identified in the strains carrying *bla*<sub>KPC-31</sub>, *bla*<sub>KPC-32</sub>, *bla*<sub>KPC-33</sub>, *bla*<sub>KPC-14</sub>, *bla*<sub>KPC-56</sub>, *bla*<sub>KPC-29</sub>, *bla*<sub>KPC-68</sub>, *bla*<sub>KPC-27</sub>, *bla*<sub>KPC-49</sub>, or *bla*<sub>KPC-115</sub>. The core structure of the ISKpn27-*bla*<sub>KPC</sub>-ISKpn6 was identified in the strains producing *bla*<sub>KPC-71</sub>, *bla*<sub>KPC-79</sub>, *bla*<sub>KPC-93</sub>, *bla*<sub>KPC-123</sub>, *bla*<sub>KPC-51</sub>, or *bla*<sub>KPC-52</sub> (Fig. 4).

## SUSCEPTIBILITY PROFILE OF THE STRAINS PRODUCING KPC VARIANTS

The *bla*<sub>KPC</sub> variants can cause a seesaw effect. On the one hand, under the pressure of CZA, the *bla*<sub>KPC</sub> sequence mutates, including *bla*<sub>KPC-8</sub> (66), *bla*<sub>KPC-30</sub>, *bla*<sub>KPC-31</sub> (36), *bla*<sub>KPC-32</sub>, *bla*<sub>KPC-40</sub> (67), *bla*<sub>KPC-41</sub> (68), *bla*<sub>KPC-50</sub> (69), and *bla*<sub>KPC-57</sub> (42), resulting in changes in the protein structure and weakening its ability to bind to avibactam, thus making the bacteria resistant to ceftazidime-avibactam [minimum inhibitory concentration (MIC) range 16–>128 mg/L]. On the other hand, the bacteria regained their susceptibility to carbapenems (especially imipenem, Table 4). In recent years, with the increasing public attention to *bla*<sub>KPC</sub> variants, studies have found that some *bla*<sub>KPC</sub> variants play avibactam-resistant ESBL profile, including *bla*<sub>KPC-14</sub> (70), *bla*<sub>KPC-28</sub> (71), *bla*<sub>KPC-33</sub> (36), *bla*<sub>KPC-46</sub>, *bla*<sub>KPC-51</sub> (72), *bla*<sub>KPC-52</sub> (72), *bla*<sub>KPC-53</sub> (73), and *bla*<sub>KPC-66</sub> (36). The ESBL phenotype-positive KPCs can be inhibited by the classic enzyme inhibitor clavulanic acid; ESBL phenotype confirmatory tests that routinely use clavulanic acid as an inhibitor often report positive results, misleading the clinicians to consider the strains as ESBL producers rather than carbapenemase producers. KPC variants producing strains tended to be inhibited by meropenem-vaborbactam. Therefore, meropenem-vaborbactam is considered a salvage therapy after failure of CZA treatment (49). It is important to note that CRE strains carrying *bla*<sub>KPC</sub> variants with decreased susceptibility to CZA can also show cross-resistance to the siderophore cephalosporin cefiderocol (74). This may be related to the fact that cefiderocol and ceftazidime are very similar in structure.

## KPC VARIANTS POSE NEW CHALLENGES FOR LABORATORY TESTING

Rapid detection of *bla*<sub>KPC</sub> is essential in treating CRE infections. Standard methods for detecting carbapenemases include both phenotypic and genotypic assays. Phenotypic assays include the Carba NP assay, modified carbapenem inactivation method (mCIM), EDTA-modified carbapenem inactivation method (eCIM), 3-aminophenylboronic acid (APB)/EDTA method, and time-of-flight mass spectrometry (86–88). Genotypic detection methods based on nucleic acid detection techniques, include GeneXpert Carba R assay (Cepheid, Sunnyvale, CA, USA), Verigene Gram-negative blood culture test (Nanosphere, Northbrook, IL, USA), and FilmArray system (bioMérieux, Marcy l'Étoile, France) (89–92). Phenotypic assays are mainly based on the ability of carbapenemases to hydrolyze carbapenems. The sensitivity and specificity of Carba NP assay, mCIM, eCIM, and APB/EDTA method are higher than 90% in detecting carbapenemases [including KPC, NDM, Verona metallo-β-lactamase (VIM), São Paulo metallo-β-lactamase (SPM)] (93–97). Moreover, phenotypic assays have been highly favored due to their low cost. However, the emergence of *bla*<sub>KPC</sub> variant genes poses significant challenges to such phenotypic assays in detecting *bla*<sub>KPC</sub> variant genes among CZA-resistant CRE (14). Since KPC-variant producing strains are often susceptible or intermediate to imipenem or meropenem, carbapenemase phenotypic assays are prone to reporting false-negative results (81). NG-Test Carba 5 and RESIST-5 O.O.K.N.V are two of the most commonly used enzyme-linked immunochromatography-based test strips. Ding et al. (14) showed that NG-Test Carba 5 effectively detected *bla*<sub>KPC-35</sub> (*n* = 3), *bla*<sub>KPC-78</sub> (*n* = 1), and *bla*<sub>KPC-79</sub> (*n* = 1), but false-negative results were observed for *bla*<sub>KPC-33</sub> (*n* = 5), *bla*<sub>KPC-71</sub> (*n* = 1), and *bla*<sub>KPC-76</sub> (*n* = 8). A similar result was obtained by Bianco et al. in which NG-Test Carba 5 and RESIST-5

TABLE 4 Antimicrobial susceptibility profiles and carbapenemase assay results of KPC variant-producing strains<sup>a</sup>

Organism	Variants	MIC (mg/L)										Carbapenemase assay					Reference								
		ETP	IPM	MEM	CZA	MEV	IMR	COL	TGC	mCIM	Rapid Carba NP	NG-Test Carba 5	RESIST-5 O.O.K.N.V	GeneXpert Carba NP	RAPIDEC Carba NP										
<i>K. pneumoniae</i>	KPC-12	256(R)	16(R)	64(R)	4(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(75)			
NA	KPC-14	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	NEG	(71)	
<i>K. pneumoniae</i>	KPC-14	ND	≤1(S)	≤0.125(S)	64(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	(12)	
<i>K. pneumoniae</i>	KPC-23	ND	512(R)	512(R)	16(R)	4(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	(76)	
<i>E. coli</i>	KPC-28	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	(71)	
<i>K. pneumoniae</i>	KPC-31	>1(R)	<0.25(S)	2(I)	>8(R)	0.125(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(44)
<i>K. pneumoniae</i>	KPC-31	ND	≤1(S)	4(R)	>256(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	NEG	ND	(12)
<i>K. pneumoniae</i>	KPC-31	ND	0.25(S)	4(R)	>64(R)	1(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(41)
<i>K. pneumoniae</i>	KPC-33	32(R)	0.5(S)	4(R)	>64(R)	2(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(14)
<i>K. pneumoniae</i>	KPC-35	16(R)	1(S)	4(R)	64(R)	2(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(14)
<i>K. pneumoniae</i>	KPC-36	>32(R)	>256(R)	>256(R)	16(R)	2(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(77)
<i>K. pneumoniae</i>	KPC-39	ND	>16(R)	>16(R)	>16(R)	16(R)	8(R)	0.5(S)	1(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(53)
<i>K. pneumoniae</i>	KPC-41	4(R)	4(R)	1(S)	>128(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(68)
<i>K. pneumoniae</i>	KPC-47	ND	>16(R)	>16(R)	>16(R)	16(R)	16(R)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	1(S)	(53)
<i>K. pneumoniae</i>	KPC-48	ND	1(S)	1(S)	>16(R)	1(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(53)
<i>E. coli</i>	KPC-49	ND	2(I)	0.5(S)	16(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(54)
<i>K. pneumoniae</i>	KPC-50	1(I)	16(R)	2(I)	>256(R)	<0.125(S)	2(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(69)
<i>K. pneumoniae</i>	KPC-51	ND	1(S)	4(R)	2048(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(72)
<i>K. pneumoniae</i>	KPC-52	ND	2(I)	2(I)	256(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(72)
<i>K. pneumoniae</i>	KPC-53	ND	2(I)	4(R)	64(R)	2(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(73)
<i>K. pneumoniae</i>	KPC-55	ND	1(S)	2(I)	0.125(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(78)
<i>K. pneumoniae</i>	KPC-70	18 mm (R)	28 mm (R)	21 mm (I)	>256(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(79)
<i>K. pneumoniae</i>	KPC-71	16(R)	0.5(S)	2(I)	>64(R)	0.5(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(14)
<i>K. pneumoniae</i>	KPC-74	16(R)	0.5(S)	1(S)	128(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(80)
<i>K. pneumoniae</i>	KPC-76	32(R)	2(I)	4(R)	>64(R)	2(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(14)
<i>K. pneumoniae</i>	KPC-78	32(R)	0.5(S)	2(I)	>64(R)	1(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(14)
<i>K. pneumoniae</i>	KPC-79	32(R)	4(R)	8(R)	64(R)	4(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(14)
<i>Citrobacter koseri</i>	KPC-82	ND	4(R)	2(I)	128(R)	0.125(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(56)
<i>K. pneumoniae</i>	KPC-94	>2(R)	≤0.5(S)	2(I)	>16(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(81)
<i>K. pneumoniae</i>	KPC-95	>2(R)	1(S)	1(S)	>16(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(81)
<i>K. pneumoniae</i>	KPC-112	ND	0.5(S)	1(S)	>128(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(82)
<i>K. pneumoniae</i>	KPC-115	0.5(S)	≤0.25(S)	≤0.5(R)	24(R)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	POS	ND	(83)
<i>K. pneumoniae</i>	KPC-121	≥256(R)	8(R)	16(R)	≥256(R)	32(R)	8(R)	0.125(S)	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	(84)

(Continued on next page)

TABLE 4 Antimicrobial susceptibility profiles and carbapenemase assay results of KPC variant-producing strains<sup>a</sup> (Continued)

Organism	Variants		MIC (mg/L)					Carbapenemase assay					Reference		
	ETP	IPM	MEM	CZA	MEV	IMR	COL	TGC	mCIM	Rapid Carba NP	NG-Test Carba 5	RESIST-5 O.O.K.N.V		GeneXpert Carba NP	RAPIDEC Carba NP
<i>Citrobacter koseri</i>	≤0.5(S)	≤0.5(S)	≤0.5(S)	64(R)	ND	ND	1(S)	≤0.25(S)	ND	ND	ND	ND	ND	ND	(85)

<sup>a</sup>MIC, minimum inhibitory concentration; KPN, *K. pneumoniae*; ECO, *E. coli*; CKO, *Citrobacter koseri*; ETP, ertapenem; IPM, imipenem; MEM, meropenem; CZA, ceftazidime-avibactam; MEV, meropenem-vaborbactam; IMR, imipenem-relebactam; COL, colistin; PB, polymyxin B; TGC, tigecycline; mCIM, modified carbapenem inactivation method; POS, positive; NEG, negative; ND, not detected.






FIG 4 Genetic sequences surrounding *bla<sub>KPC</sub>* carbapenemase genes.

O.O.K.N.V could detect *bla*<sub>KPC-14</sub> ( $n = 2$ ), but could not detect *bla*<sub>KPC-31</sub> ( $n = 4$ ) and *bla*<sub>KPC-33</sub> ( $n = 2$ ) (12). The false-negative results of enzyme immunoassay in detecting *bla*<sub>KPC</sub> variants may be related to the mutation site, which changes the target site of carbapenemase binding to the antibody and thus fails to bind to the antibody, resulting in false-negative results.

KPC variants may challenge the performance of some classical carbapenemase detection methods used by clinical laboratories. PCR assay may be suitable to detect *bla*<sub>KPC</sub> variant. The GeneXpert Carba R assay is a qualitative, *in vitro* real-time PCR assay designed to detect five carbapenemase gene families, including *bla*<sub>IMP</sub>, *bla*<sub>KPC-2 or 3</sub>, *bla*<sub>NDM</sub>, *bla*<sub>OXA-48</sub>, and *bla*<sub>VIM</sub>, with more than 96% sensitivity and specificity (90, 92, 98). Ding et al. (14) showed that GeneXpert Carba R has potential advantage in detecting *bla*<sub>KPC</sub> variant due to its detection principle, which is not affected by gene locus variation and can effectively detect *bla*<sub>KPC-33</sub> ( $n = 5$ ), *bla*<sub>KPC-35</sub> ( $n = 3$ ), *bla*<sub>KPC-71</sub> ( $n = 1$ ), *bla*<sub>KPC-76</sub> ( $n = 8$ ), *bla*<sub>KPC-78</sub> ( $n = 1$ ), and *bla*<sub>KPC-79</sub> ( $n = 1$ ). Several studies showed that the presence of the novel *bla*<sub>KPC-46</sub>, *bla*<sub>KPC-66</sub>, *bla*<sub>KPC-92</sub>, *bla*<sub>KPC-94</sub>, and *bla*<sub>KPC-95</sub> were confirmed by the X-pert Carba R assay (81, 99). A similar study compared three carbapenemase detection methods, including GeneXpert Carba R, NG-Test Carba 5, and colloidal gold immunoassay test, to evaluate the performance of these methods in detecting KPC variants protein. The result showed that GeneXpert Carba R can confirm the presence of all 13 types of KPC variant protein, including KPC-2, KPC-3, KPC-25, KPC-33, KPC-35, KPC-51, KPC-52, KPC-71, KPC-76, KPC-77, KPC-78, KPC-93, and KPC-123 (100). There are other methods for detecting carbapenemases based on PCR amplification, such as Verigene Gram-negative blood culture test (Nanosphere, Northbrook, IL, USA), FilmArray system (bioMérieux, Marcy l'Étoile, France), etc., but there are no published data on the performance of these methods in detecting KPC variants (91). Different methods for detecting KPC variants may get different results. The laboratories need to pay attention to this special phenomenon. When the conventional carbapenemase detection method shows negative results, but the bacteria show resistance to CZA, further molecular testing is required to determine whether bacteria produce carbapenemase.

The emergence of KPC variants disrupts conventional laboratory thinking about carbapenemase detection and changes the practice of inferring bacterial susceptibility to CZA from carbapenemase detection results (most automated susceptibility testing systems do not yet include CZA). The reporting of false-negative carbapenemase results is likely to mislead clinicians in their anti-infective treatment. Based on the above information, we believe that CZA susceptibility testing should be performed concurrently with carbapenemase testing, and KPC variants can be identified early by combining the antimicrobial susceptibility phenotype and carbapenemase results to provide more information early to start precision treatment of infections caused by KPC variants.

## CURRENTLY AVAILABLE TREATMENT OPTIONS

### Carbapenems

Since several KPC-variant producing strains regained susceptibility to imipenem or meropenem while remaining resistant to CZA, this suggests the potential value of carbapenems in the treatment of infections caused by KPC-variant strains. Sporadic cases of treatment success have been reported for meropenem alone (increased dose, extended infusion time) or in combination with other antimicrobial agents in managing infections caused by KPC variant-producing *K. pneumoniae* (45, 52). However, meropenem or other antimicrobial combinations have also shown a high failure rate in treating such resistant strains in some cases when the *bla*<sub>KPC</sub> variant reverts to the original *bla*<sub>KPC-2</sub> during treatment, allowing the bacteria to regain carbapenem resistance (11, 51, 57). Carbapenem therapy was associated with a 50% all-cause mortality rate in patients infected with KPC variant producer (usually related to clinical failure), which is much higher than that observed in patients with ESBL-producing *K. pneumoniae* infections and similar to that observed in KPC-2/3-producing *K. pneumoniae* infections not treated

with CZA (53). The limited data currently available suggest that most *bla*<sub>KPC</sub> variants occur during CZA treatment. As previously described, CZA inhibits KPC-2 or KPC-3, while meropenem or imipenem provides potent activity against most KPC variants. Since the bacteria may revert to classical *bla*<sub>KPC</sub> phenotypes such as *bla*<sub>KPC-2</sub> or *bla*<sub>KPC-3</sub> producer in response to environmental changes when treated with carbapenems alone to which the bacterial isolates were susceptible, is it possible that an antimicrobial regimen of carbapenems combined with CZA could effectively cover both the KPC-2/3 and KPC variants producing strains, thus preventing the chance of clonal transformation of bacteria? Should we try this approach to meet the clinical needs? However, such combinations in treating KPC variant-producing bacterial infections are rarely reported (57). The efficacy and safety must also be validated by further data from *in vitro* or *in vivo* studies.

## New $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations

### *Meropenem-vaborbactam*

Vaborbactam is a non- $\beta$ -lactam serine  $\beta$ -lactamase inhibitor based on a cyclic boronic acid pharmacophore (101). Meropenem-vaborbactam inhibits the activity of class A serine enzymes (including ESBLs and KPC) and AmpCs, but not OXA-48 carbapenemases and metallo- $\beta$ -lactamases (102). Meropenem-vaborbactam was approved by the U.S. Food and Drug Administration in 2017 for treating complicated urinary tract infections (cUTIs) in adults and by the European Medicines Agency in 2018 for treating cUTIs, complicated intra-abdominal infections, or hospital-acquired pneumonia and bacteremia occurring in association (or suspected association) with any of these infections (103). In the European Union, meropenem-vaborbactam is also indicated for treating infections caused by aerobic Gram-negative bacteria in adults with limited options. In a study by Lapuebla et al. evaluating the activity of meropenem-vaborbactam against KPC-producing *Enterobacterales*, the combination inhibited 98.5% (131/133) of isolates at 1/8 mg/L (104). A global multicenter epidemiological study in 2014 included 10,426 *Enterobacterales* strains,  $\leq 2/8$  mg/L of meropenem-vaborbactam inhibited 99.3% of the strains tested (105). Subsequent studies on 11,559 *Enterobacterales* strains collected in 2015 found that meropenem-vaborbactam inhibited 99.5% of KPC-producing *Enterobacterales* at a concentration of 4/8 mg/L (106). Studies have also shown potent *in vitro* activity of meropenem-vaborbactam against the *K. pneumoniae* strains producing KPC variants, including KPC-14, KPC-28, KPC-31, KPC-33, KPC-35, KPC-39, KPC-50, KPC-71, KPC-76, KPC-78, or KPC-79 (14, 107, 108). A retrospective study collected 12 KPC variant-producing *K. pneumoniae* isolates from ICU patients between November 2020 to January 2021, including KPC-62 ( $n = 11$ ) and KPC-31 ( $n = 1$ ) (109). The result showed that all strains that carried KPC variant were resistant to CZA (MIC  $\geq 64$  mg/L), but susceptible to meropenem-vaborbactam (MIC range, 0.25/8 mg/L  $\sim$  2/8 mg/L) (109). Case reports have shown that meropenem-vaborbactam can successfully cure bacteremia caused by KPC-31 producers, suggesting that meropenem-vaborbactam may be a new option for treating infections caused by KPC variant-producing *Enterobacterales* strains (49). Similarly, meropenem-vaborbactam has successfully treated infections caused by KPC-82-producing *Citrobacter koseri* (56).

### *Imipenem-relebactam*

Relebactam is a new  $\beta$ -lactamase inhibitor with a diazabicyclooctane core, similar to avibactam (110). Imipenem-relebactam inhibits class A serine enzymes (including ESBLs and KPC) and AmpCs, but not OXA-48 carbapenemase, metallo- $\beta$ -lactamase, or class A carbapenemase GES-20 (111). The Study for Monitoring Antimicrobial Resistance Trends reported that relebactam restored susceptibility to imipenem in 80.5%, 100%, and 74.1% of imipenem-nonsusceptible *Pseudomonas aeruginosa*, *Enterobacteriaceae*, and *K. pneumoniae*, in 2015 (112). A study by Papp-Wallace et al. showed that all *Enterobacterales* strains were highly susceptible to imipenem-relebactam (MIC  $\leq 2$  mg/L) (113). A

study by Carpenter et al. also showed similar results, with imipenem-relebactam being the most active combination against CRE ( $MIC_{50/90} \leq 0.25/0.5$  mg/L) (114). *In vitro* studies have also shown excellent activity of imipenem-relebactam against the *K. pneumoniae* strains producing KPC variants, including KPC-31, KPC-33, KPC-35, and KPC-62 (109, 115). Therefore, it may be speculated that imipenem-relebactam has good *in vitro* antimicrobial activity against KPC variants. At the same time, imipenem-relebactam has good antimicrobial activity against KPC-2- or KPC-3-producing *Enterobacterales*, so in theory, using imipenem-relebactam in treating KPC variant infection can effectively prevent the emergence of KPC-2/3-producing strains.

### **Aztreonam-avibactam**

The infections caused by metallo- $\beta$ -lactamase-producing strains remain a major challenge in clinical treatment because avibactam, vaborbactam, and relebactam can not inhibit the activity of metallo- $\beta$ -lactamases. However, the aztreonam-avibactam combination is highly anticipated because metallo- $\beta$ -lactamases do not hydrolytically destroy the antimicrobial activity of aztreonam, and so aztreonam-avibactam can inhibit the *Enterobacterales* strains producing either class A serinease, metallo- $\beta$ -lactamase, or class D OXA-48 carbapenemase (116). Interestingly, some KPC variant-producing strains regained susceptibility to carbapenems while simultaneously regaining susceptibility to aztreonam. KPC-31, KPC-33, KPC-49, and KPC-94 producers showed high susceptibility to aztreonam (MIC range:  $\leq 0.5$ –4 mg/L), but KPC-95-, KPC-82-, KPC-55-, and KPC-14-producing strains remained resistant to aztreonam (MIC >16 mg/L) (54, 70, 81). Our results showed (Li Ding, et al. data unpublished) that the *K. pneumoniae* strains producing KPC variant (including KPC-33, KPC-35, KPC-71, KPC-76, KPC-78, KPC-79, and KPC-112) were highly susceptible to aztreonam-avibactam (MIC ranges, 2/4–4/4 mg/L).

### **Other antimicrobial agents**

#### **Tigecycline**

Tigecycline belongs to a new class of glycylcycline antibiotics. It has been touted as one of the last lines of defense in treating complex infections caused by multi-drug resistant Gram-negative and Gram-positive bacteria. Binding to bacterial 30S ribosomes prevents the entry of transfer RNA. It prevents amino acids from integration into peptide chains, ultimately blocking bacterial protein synthesis and limiting bacterial growth. It has great *in vitro* antimicrobial activity against class A, B, C, and D  $\beta$ -lactamase-producing *Enterobacterales* (117). Scattered studies have shown that tigecycline has high *in vitro* antimicrobial activity against KPC variant-producing *Enterobacterales* (55, 82). But an excess mortality risk was demonstrated in comparative clinical trials (118). While it is generally not recommended for treating bacteremia because of its low steady-state concentrations in serum following the current dosing recommendation, tigecycline is primarily used in combination regimens when treating carbapenem-resistant Gram-negative infections (119). However, the emergence of tigecycline-resistant strains has recently been reported (120). Overexpression of resistance-nodulation-division efflux pumps such as AcrAB is an essential molecular mechanism underlying tigecycline resistance (121). Additionally, *tet(X)* gene variants are newly emerging mechanisms of tigecycline resistance (122, 123).

#### **Polymyxin**

Polymyxins are an “old” class of lipopeptide antibiotics approved in the late 1950s (124). Polymyxins have regained public attention due to their excellent activity against CRE, CRPA, and CRAB. The two clinically available polymyxins, colistin and polymyxin B, demonstrate comparable spectra of antibacterial activity, mechanism of action, and resistance profile because of their similar structures (125). CHINET report in 2018 showed that polymyxin B had excellent *in vitro* activity against 272 clinical isolates of CRKP

(93.8% susceptible) (126). However, nephrotoxicity and heteroresistance are two major limitations of polymyxins (125, 127).

Modification of lipid A portion of lipopolysaccharide (LPS) is the main mechanism of *Enterobacteriales* resistant to polymyxin, which can be caused by chromosomal mutations in genes of the two-component system involved in LPS modification, namely *PhoPQ*, *PmrAB*, and *CrrAB*, and *MgrB* (128). Additionally, plasmid-mediated polymyxin resistance gene *mcr-1* can also mediate strains resistant to polymyxin (129). Several studies showed that KPC variants did not affect the susceptibility of polymyxin, suggesting that polymyxin still has potential advantages in treating KPC variant infections (41, 55).

## FUTURE OUTLOOK

To address the challenges posed by the global spread of *bla*<sub>KPC</sub> variants, multiple studies need to be conducted to curb the infections caused by these bacteria. Firstly, countries need to establish a collaborative surveillance network for the *bla*<sub>KPC</sub> to survey the spread of KPC variant producers in real-time and carry out proactive hospital infection control measures to curb the spread. Secondly, more effective antimicrobial agents need to be developed continuously to deal with infections and be used rationally to avoid the emergence of the resistant strain. Countries should open fast-track approval channels for new drugs to be used to save patients as soon as possible. Thirdly, clinical microbiology laboratories should strengthen the routine detection and inform *bla*<sub>KPC</sub> variant-positive isolates. *In vitro* diagnostic companies need to develop methods that can accurately and timely detect new *bla*<sub>KPC</sub> variants. The manufacturers of automated antimicrobial susceptibility testing systems should add carbapenemase testing and report the result of KPC carbapenemases in advance based on clinical need. Rapid whole-genome sequencing should be applied to predict the resistance profile mediated by KPC variants. In the context of limited treatment options currently available, there is an urgent need to develop treatment guidelines for infections caused by KPC variant producers. Finally, ARC (avibactam-resistant carbapenemase) is classified as a class A enzyme. The designation of KPC variants is currently confusing. Some KPC variants are designated as ESBLs and some KPC variants are named as carbapenemases. More KPC variants are being reported, and more are expected in the future. Although the sequence difference between KPC variants and KPC wild type is not significant, the corresponding antimicrobial susceptibility profile and detection techniques are very different. The traditional KPC inhibitor APB cannot inhibit the activity of ARC. Such ARC enzymes should be named separately to attract attention.

## ACKNOWLEDGMENTS

We thank Chun Yu liushuang and Zhong Xiang from Pfizer China Medical Infectious Diseases Team for collecting some data.

This work was supported by the National Natural Science Foundation of China (grant numbers 32141002, 82172311 and 82302574) and the China Antimicrobial Surveillance Network (Independent Medical Grants from Pfizer, 2020QD049). The funders had no role in the study design, data collection, analysis, publishing decisions, or manuscript preparation.

## AUTHOR AFFILIATIONS

<sup>1</sup>Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China

<sup>2</sup>Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China

<sup>3</sup>Hangzhou Matridx Biotechnology Co., Ltd., Hangzhou, Zhejiang, China

## AUTHOR ORCIDs

Li Ding  <http://orcid.org/0009-0001-1436-3668>



Siquan Shen  <http://orcid.org/0000-0002-1537-0333>

Yan Guo  <http://orcid.org/0009-0008-0407-8979>

Fupin Hu  <http://orcid.org/0000-0002-4493-0619>

## FUNDING

Funder	Grant(s)	Author(s)
National Natural Science Foundation of China (NSFC)	32141002, 82172311, 82302574	Fupin Hu Li Ding
China Antimicrobial Surveillance Network	2020QD049	Fupin Hu

## REFERENCES

- Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, Lee BY. 2017. Potential economic burden of carbapenem-resistant *Enterobacteriaceae* (CRE) in the United States. *Clin Microbiol Infect* 23:48. <https://doi.org/10.1016/j.cmi.2016.09.003>
- Martin A, Fahrbach K, Zhao Q, Lodise T. 2018. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to *Enterobacteriaceae*: results of a systematic literature review and meta-analysis. *Open Forum Infect Dis* 5:ofy150. <https://doi.org/10.1093/ofid/ofy150>
- Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, et al. 2022. Clinical outcomes and bacterial characteristics of Carbapenem-resistant *Klebsiella pneumoniae* complex among patients from different global regions (CRACKLE-2): A prospective, Multicentre, cohort study. *Lancet Infect Dis* 22:401–412. [https://doi.org/10.1016/S1473-3099\(21\)00399-6](https://doi.org/10.1016/S1473-3099(21)00399-6)
- Yang W, Ding L, Han R, Yin D, Wu S, Yang Y, Zhu D, Guo Y, Hu F, Xu Y, et al, on behalf of the China Antimicrobial Surveillance Network (CHINET) Study Group. 2023. Current status and trends of antimicrobial resistance among clinical isolates in China: A retrospective study of CHINET from 2018 to 2022. *One Health Adv* 1:8. <https://doi.org/10.1186/s44280-023-00009-9>
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavalieri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 18:318–327. [https://doi.org/10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3)
- Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, Zheng Y, Guo Y, Zhang R, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group. 2020. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant *Enterobacteriaceae* isolated from adult and children patients in China. *Front Cell Infect Microbiol* 10:314. <https://doi.org/10.3389/fcimb.2020.00314>
- de Jonge BLM, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. 2016. *in vitro* susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible *Enterobacteriaceae* isolates collected during the INFORM global surveillance study (2012 to 2014). *Antimicrob Agents Chemother* 60:3163–3169. <https://doi.org/10.1128/AAC.03042-15>
- Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BLM, Bouchillon SK, Sahm DF, Bradford PA. 2016. Global dissemination of *bla*<sub>KPC</sub> into bacterial species beyond *Klebsiella pneumoniae* and *in vitro* susceptibility to ceftazidime-avibactam and aztreonam-avibactam. *Antimicrob Agents Chemother* 60:4490–4500. <https://doi.org/10.1128/AAC.00107-16>
- Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group. 2019. Results from the China antimicrobial surveillance network (CHINET) in 2017 of the *in vitro* activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of *Enterobacteriaceae* and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 63:e02431-18. <https://doi.org/10.1128/AAC.02431-18>
- Zasowski EJ, Rybak JM, Rybak MJ. 2015. The  $\beta$ -lactams strike back: ceftazidime-avibactam. *Pharmacotherapy* 35:755–770. <https://doi.org/10.1002/phar.1622>
- Shi Q, Yin D, Han R, Guo Y, Zheng Y, Wu S, Yang Y, Li S, Zhang R, Hu F. 2020. Emergence and recovery of ceftazidime-avibactam resistance in *bla*<sub>KPC-33</sub>-harboring *Klebsiella pneumoniae* sequence type 11 isolates in China. *Clin Infect Dis* 71:S436–S439. <https://doi.org/10.1093/cid/ciaa1521>
- Bianco G, Boattini M, Iannaccone M, Bondi A, Ghibaudo D, Zanotto E, Peradotto M, Cavallo R, Costa C. 2021. Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing *Enterobacteriales*: a 2-year experience. *J Glob Antimicrob Resist* 24:411–414. <https://doi.org/10.1016/j.jgar.2021.02.008>
- Shen S, Shi Q, Hu F. 2022. The changing face of *Klebsiella pneumoniae* carbapenemase: *in-vivo* mutation in patient with chest infection. *The Lancet* 399:2226. [https://doi.org/10.1016/S0140-6736\(22\)01011-X](https://doi.org/10.1016/S0140-6736(22)01011-X)
- Ding L, Shi Q, Han R, Yin D, Wu S, Yang Y, Guo Y, Zhu D, Hu F. 2021. Comparison of four carbapenemase detection methods for *bla*<sub>KPC-2</sub> variants. *Microbiol Spectr*:9:e0095421.
- Karaiskos I, Daikos GL, Gkoufa A, Adamis G, Stefos A, Symbardi S, Chrysos G, Filiou E, Basoulis D, Mouloudi E, Galani L, Akinosoglou K, Arvaniti K, Masgala A, Petraki M, Papadimitriou E, Galani I, Poulakou G, Routsis C, Giamarellou H, Hellenic Ceftazidime/Avibactam Registry Study Group. 2021. Ceftazidime/avibactam in the era of carbapenemase-producing *Klebsiella pneumoniae*: experience from a national registry study. *J Antimicrob Chemother* 76:775–783. <https://doi.org/10.1093/jac/dkaa503>
- Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, De Rosa FG, Sarmati L, Bassetti M, Brindicci G, Rossi M, et al. 2021. Ceftazidime-Avibactam use for *Klebsiella pneumoniae* Carbapenemase-producing *K. pneumoniae* infections: A retrospective observational multicenter study. *Clin Infect Dis* 73:1664–1676. <https://doi.org/10.1093/cid/ciab176>
- Tumbarello M, Treccarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, Tascini C, Parruti G, Pallotto C, Sica S, Concia E, Cultrera R, De Pascale G, Capone A, Antinori S, Corcione S, Righi E, Losito AR, Digaetano M, Amadori F, Giacobbe DR, Ceccarelli G, Mazza E, Raffaelli F, Spanu T, Cauda R, Viale P. 2019. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *Clin Infect Dis* 68:355–364. <https://doi.org/10.1093/cid/ciy492>
- Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. 2022. Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum  $\beta$ -lactamase producing enterobacteriales (ESBL-E), carbapenem-resistant Enterobacteriales (CRE), and *Pseudomonas aeruginosa* with difficult-to-treat resistance (DTR-*P. aeruginosa*). *Clin Infect Dis* 75:187–212. <https://doi.org/10.1093/cid/ciac268>
- Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing *Klebsiella pneumoniae* isolate. *Antimicrob Agents Chemother* 59:6605–6607. <https://doi.org/10.1128/AAC.01165-15>



20. Shapiro AB, Moussa SH, Carter NM, Gao N, Miller AA. 2021. Ceftazidime-avibactam resistance mutations V240G, D179Y, and D179Y/T243m in KPC-3  $\beta$ -lactamase do not alter cefpodoxime-EtTX1317 susceptibility. *ACS Infect Dis* 7:79–87. <https://doi.org/10.1021/acscinfed.0c00575>
21. Bratu S, Landman D, Alam M, Tolentino E, Quale J. 2005. Detection of KPC carbapenem-hydrolyzing enzymes in *Enterobacter Spp.* from Brooklyn, New York. *Antimicrob Agents Chemother* 49:776–778. <https://doi.org/10.1128/AAC.49.2.776-778.2005>
22. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. 2001. Novel carbapenem-hydrolyzing beta-Lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 45:1151–1161. <https://doi.org/10.1128/AAC.45.4.1151-1161.2001>
23. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. 2010. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. *Antimicrob Agents Chemother* 54:890–897. <https://doi.org/10.1128/AAC.00693-09>
24. Munoz-Price LS, Quinn JP. 2009. The spread of *Klebsiella pneumoniae* carbapenemases: a tale of strains, plasmids, and transposons. *Clin Infect Dis* 49:1739–1741. <https://doi.org/10.1086/648078>
25. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. 2009. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob Agents Chemother* 53:3365–3370. <https://doi.org/10.1128/AAC.00126-09>
26. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y, Israel Carbapenem-Resistant Enterobacteriaceae Working Group. 2011. Containment of a country-wide outbreak of carbapenem-resistant *Klebsiella pneumoniae* in Israeli hospitals via a nationally implemented intervention. *Clin Infect Dis* 52:848–855. <https://doi.org/10.1093/cid/cir025>
27. Warburg G, Hidalgo-Grass C, Partridge SR, Tolmasey ME, Temper V, Moses AE, Block C, Strahilevitz J. 2012. A Carbapenem-resistant *Klebsiella pneumoniae* epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6)-Ib. *J Antimicrob Chemother* 67:898–901. <https://doi.org/10.1093/jac/dkr552>
28. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti M, Bordi E, Capozzi D, Balice MP, Tarasi A, Parisi G, Lappa A, Carattoli A, Petrosillo N. 2013. High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect* 19:E23–E30. <https://doi.org/10.1111/1469-0691.12070>
29. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, Gales AC, Venezia SN, Quinn JP, Nordmann P. 2010. Worldwide diversity of *Klebsiella pneumoniae* that produce beta-Lactamase bla<sub>KPC-2</sub> gene. *Emerg Infect Dis* 16:1349–1356. <https://doi.org/10.3201/eid1609.091389>
30. Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. 2011. ST11, the dominant clone of KPC-producing *Klebsiella pneumoniae* in China. *J Antimicrob Chemother* 66:307–312. <https://doi.org/10.1093/jac/dkq431>
31. Pereira PS, de Araujo CFM, Seki LM, Zahner V, Carvalho-Assef APD, Asensi MD. 2013. Update of the molecular epidemiology of KPC-2-producing *Klebsiella pneumoniae* in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340). *J Antimicrob Chemother* 68:312–316. <https://doi.org/10.1093/jac/dks396>
32. Shen P, Wei Z, Jiang Y, Du X, Ji S, Yu Y, Li L. 2009. Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among enterobacteriaceae in China. *Antimicrob Agents Chemother* 53:4333–4338. <https://doi.org/10.1128/AAC.00260-09>
33. Naas T, Cuzon G, Villegas M-V, Lartigue M-F, Quinn JP, Nordmann P. 2008. Genetic structures at the origin of acquisition of the beta-lactamase bla<sub>KPC</sub> gene. *Antimicrob Agents Chemother* 52:1257–1263. <https://doi.org/10.1128/AAC.01451-07>
34. Chen L, Mathema B, Chavda KD, DeLeo FR, Bonomo RA, Kreiswirth BN. 2014. Carbapenemase-producing *Klebsiella pneumoniae*: molecular and genetic decoding. *Trends Microbiol* 22:686–696. <https://doi.org/10.1016/j.tim.2014.09.003>
35. Wolter DJ, Kurpiel PM, Woodford N, Palepou M-F, Goering RV, Hanson ND. 2009. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. *Antimicrob Agents Chemother* 53:557–562. <https://doi.org/10.1128/AAC.00734-08>
36. Carattoli A, Arcari G, Bibbolino G, Sacco F, Tomolillo D, Di Lella FM, Trancassini M, Faino L, Venditti M, Antonelli G, Raponi G. 2021. Evolutionary Trajectories toward Ceftazidime-Avibactam resistance in *Klebsiella pneumoniae* clinical isolates. *Antimicrob Agents Chemother* 65:e0057421. <https://doi.org/10.1128/AAC.00574-21>
37. Bianco G, Boattini M, Iannaccone M, Cavallo R, Costa C. 2020. Bloodstream infection by two subpopulations of *Klebsiella pneumoniae* ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay. *J Antimicrob Chemother* 75:3075–3076. <https://doi.org/10.1093/jac/dkaa283>
38. Yang Q, Li Y, Fang L, Lei T, Cai H, Hua X, Zheng M, Yu Y. 2023. A novel KPC-113 variant conferring carbapenem and ceftazidime-avibactam resistance in a multidrug-resistant *Pseudomonas aeruginosa* isolate. *Clin Microbiol Infect* 29:387. <https://doi.org/10.1016/j.cmi.2022.10.013>
39. Piccirilli A, Cherubini S, Celenza G, Rossolini GM, Brisidelli F, Segatore B, Principe L, Luzzaro F, Andriani L, Amicosante G, Perilli M. 2022. A two amino acid duplication, L167E168, in the  $\Omega$ -loop drastically decreases carbapenemase activity of KPC-53, a natural class A  $\beta$ -lactamase. *Antimicrob Agents Chemother* 66:e0240221. <https://doi.org/10.1128/aac.02402-21>
40. Alsenani TA, Viviani SL, Kumar V, Taracila MA, Bethel CR, Barnes MD, Papp-Wallace KM, Shields RK, Nguyen MH, Clancy CJ, Bonomo RA, van den Akker F. 2022. Structural characterization of the D179N and D179Y variants of KPC-2  $\beta$ -lactamase:  $\Omega$ -loop destabilization as a mechanism of resistance to ceftazidime-avibactam. *Antimicrob Agents Chemother* 66:e0241421. <https://doi.org/10.1128/aac.02414-21>
41. Shi Q, Yin D, Han R, Guo Y, Zheng Y, Wu S, Yang Y, Li S, Zhang R, Hu F. 2020. Emergence and recovery of ceftazidime-avibactam resistance in bla<sub>KPC-33</sub>-harboring *Klebsiella pneumoniae* sequence type 11 isolates in China. *Clin Infect Dis* 71:5436–5439. <https://doi.org/10.1093/cid/ciaa1521>
42. Galani I, Karaiskos I, Angelidis E, Papoutsaki V, Galani L, Souli M, Antoniadou A, Giamarellou H. 2021. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing *Klebsiella pneumoniae* of sequence type 39 during treatment. *Eur J Clin Microbiol Infect Dis* 40:219–224. <https://doi.org/10.1007/s10096-020-04000-9>
43. Antonelli A, Gianni T, Di Pilato V, Riccobono E, Perriello G, Mencacci A, Rossolini GM. 2019. KPC-31 expressed in a ceftazidime/avibactam-resistant *Klebsiella pneumoniae* is associated with relevant detection issues. *J Antimicrob Chemother* 74:2464–2466. <https://doi.org/10.1093/jac/dkz156>
44. Tiseo G, Falcone M, Leonildi A, Giordano C, Barnini S, Arcari G, Carattoli A, Menichetti F. 2021. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 *Klebsiella pneumoniae*-producing KPC-31, a D179Y variant of KPC-3. *Open Forum Infect Dis* 8:ofab141. <https://doi.org/10.1093/ofid/ofab141>
45. Arcari G, Oliva A, Sacco F, Di Lella FM, Raponi G, Tomolillo D, Curtolo A, Venditti M, Carattoli A. 2022. Interplay between *Klebsiella pneumoniae* producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report. *Eur J Clin Microbiol Infect Dis* 41:495–500. <https://doi.org/10.1007/s10096-021-04388-y>
46. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla<sub>KPC-3</sub> mutations during treatment of carbapenem-resistant *Klebsiella pneumoniae* infections. *Antimicrob Agents Chemother* 61:e02097-16. <https://doi.org/10.1128/AAC.02097-16>
47. Räsänen K, Koivula I, Ilmavirta H, Puranen S, Kallonen T, Lyytikäinen O, Jalava J. 2019. Emergence of ceftazidime-avibactam-resistant *Klebsiella pneumoniae* during treatment, Finland. *Euro Surveill* 24:19. <https://doi.org/10.2807/1560-7917.ES.2019.24.19.1900256>
48. Göttig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S, Wichelhaus TA. 2019. Emergence of ceftazidime/avibactam resistance in KPC-3-producing *Klebsiella pneumoniae in vivo*. *J Antimicrob Chemother* 74:3211–3216. <https://doi.org/10.1093/jac/dkz330>
49. Athans V, Neuner EA, Hassouna H, Richter SS, Keller G, Castanheira M, Brizendine KD, Mathers AJ. 2019. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant *Klebsiella pneumoniae*

- bacteremia and abscess in a liver transplant recipient. *Antimicrob Agents Chemother* 63:e01551-18. <https://doi.org/10.1128/AAC.01551-18>
50. Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, Pongolini S, Berlinger A, Cristini F, Bartoletti M, Tedeschi S, Ambretti S. 2018. *In vivo* evolution of resistant subpopulations of KPC-producing *Klebsiella pneumoniae* during ceftazidime/avibactam treatment. *J Antimicrob Chemother* 73:1525–1529. <https://doi.org/10.1093/jac/dky082>
  51. Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, McConville TH, Mehta M, Gomez-Simmonds A, Uhlemann AC. 2018. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in *bla*<sub>KPC-2</sub>-harboring *Klebsiella pneumoniae* sequence type 307 isolates. *Antimicrob Agents Chemother* 62:e02101-17. <https://doi.org/10.1128/AAC.02101-17>
  52. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in *Klebsiella pneumoniae* carbapenemase-producing K pneumoniae: a case report and review of literature. *Open Forum Infect Dis* 4. <https://doi.org/10.1093/ofid/ofx101>
  53. Cano Á, Guzmán-Puche J, García-Gutiérrez M, Castón JJ, Gracia-Ahufinger I, Pérez-Nadales E, Recio M, Natera AM, Marfil-Pérez E, Martínez-Martínez L, Torre-Cisneros J. 2020. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing *Klebsiella pneumoniae* infections: report of a case and review of the literature. *J Glob Antimicrob Resist* 22:9–12. <https://doi.org/10.1016/j.jgar.2019.11.007>
  54. Hernández-García M, Sánchez-López J, Martínez-García L, Becerra-Aparicio F, Morosini MI, Ruiz-Garbajosa P, Cantón R. 2021. Emergence of the new KPC-49 variant conferring an ESBL phenotype with resistance to ceftazidime-avibactam in the ST131-H30R1 *Escherichia Coli* high-risk clone. *Pathogens* 10:67. <https://doi.org/10.3390/pathogens10010067>
  55. Shi Q, Han R, Guo Y, Yang Y, Wu S, Ding L, Zhang R, Yin D, Hu F. 2022. Multiple novel ceftazidime-avibactam-resistant variants of *bla*<sub>KPC-2</sub>-positive *Klebsiella pneumoniae* in two patients. *Microbiol Spectr*. <https://doi.org/10.1128/spectrum.01714-21:e0171421>
  56. Lebreton F, Corey BW, McElheny CL, Iovleva A, Preston L, Margulieux KR, Cybulski RJ, Mc Gann P, Doi Y, Bennett JW. 2021. Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of *Citrobacter koseri*. *Antimicrob Agents Chemother* 65:e0015021. <https://doi.org/10.1128/AAC.00150-21>
  57. Ding L, Shen S, Han R, Yin D, Guo Y, Hu F. 2022. Ceftazidime-avibactam in combination with imipenem as salvage therapy for ST11 KPC-33-producing *Klebsiella pneumoniae* Antibiotics (Basel) 11:5. <https://doi.org/10.3390/antibiotics11050604>
  58. Corcione S, De Benedetto I, Shbaklo N, Torsello G, Lupia T, Bianco G, Cavallo R, Brazzi L, Montrucchio G, De Rosa FG. 2023. Ceftazidime-avibactam (C/A) resistant, meropenem sensitive KPC-producing *Klebsiella pneumoniae* in ICU setting: we are what we are treated with? *Int J Mol Sci* 24:4767. <https://doi.org/10.3390/ijms24054767>
  59. Chen L, Chavda KD, Melano RG, Jacobs MR, Levi MH, Bonomo RA, Kreiswirth BN. 2013. Complete sequence of a *bla*<sub>KPC-2</sub>-harboring incfii(K1) plasmid from a *Klebsiella pneumoniae* sequence type 258 strain. *Antimicrob Agents Chemother* 57:1542–1545. <https://doi.org/10.1128/AAC.02332-12>
  60. Andrade LN, Curiao T, Ferreira JC, Longo JM, Clímaco EC, Martinez R, Bellissimo-Rodrigues F, Basile-Filho A, Evaristo MA, Del Peloso PF, Ribeiro VB, Barth AL, Paula MC, Baquero F, Cantón R, Darini AL da C, Coque TM. 2011. Dissemination of *bla*<sub>KPC-2</sub> by the spread of *Klebsiella pneumoniae* clonal complex 258 clones (ST258, ST11, ST437) and plasmids (IncFII, IncN, IncI/M) among enterobacteriaceae species in Brazil. 55:3579–3583. *Antimicrob Agents Chemother* 55:3579–3583. <https://doi.org/10.1128/AAC.01783-10>
  61. Huang J, Hu X, Zhao Y, Shi Y, Ding H, Wu R, Zhao Z, Ji J. 2019. Comparative analysis of *bla*<sub>KPC</sub> expression in Tn4401 transposons and the Tn3-Tn4401 Chimera. *Antimicrob Agents Chemother* 63:e02434–18. <https://doi.org/10.1128/AAC.02434-18>
  62. Cheruvanky A, Stoesser N, Sheppard AE, Crook DW, Hoffman PS, Weddle E, Carroll J, Sifri CD, Chai W, Barry K, Ramakrishnan G, Mathers AJ. 2017. Enhanced *Klebsiella pneumoniae* carbapenemase expression from a novel Tn4401 deletion. *Antimicrob Agents Chemother* 61:e00025-17. <https://doi.org/10.1128/AAC.00025-17>
  63. Octavia S, Kalisvar M, Venkatachalam I, Ng OT, Xu W, Sridatta PSR, Ong YF, Wang LD, Chua A, Cheng B, Lin RTP, Teo JWP. 2019. *Klebsiella pneumoniae* and *Klebsiella quasipneumoniae* define the population structure of *bla*<sub>KPC-2</sub>*Klebsiella*: a 5 year retrospective genomic study in Singapore. *J Antimicrob Chemother* 74:3205–3210. <https://doi.org/10.1093/jac/dkz332>
  64. Fu P, Tang Y, Li G, Yu L, Wang Y, Jiang X. 2019. Pandemic spread of *bla*<sub>KPC-2</sub> among *Klebsiella pneumoniae* ST11 in China is associated with horizontal transfer mediated by Incfii-like plasmids. *Int J Antimicrob Agents* 54:117–124. <https://doi.org/10.1016/j.ijantimicag.2019.03.014>
  65. Zhang W, Zhu Y, Wang C, Liu W, Li R, Chen F, Luan T, Zhang Y, Schwarz S, Liu S. 2019. Characterization of a multidrug-resistant porcine *Klebsiella pneumoniae* sequence type 11 strain coharboring *bla*<sub>KPC-2</sub> and fosA3 on two novel hybrid plasmids. *mSphere* 4:e00590-19. <https://doi.org/10.1128/mSphere.00590-19>
  66. Piazza A, Caltagirone M, Bitar I, Nucleo E, Spalla M, Fogato E, D'Angelo R, Pagani L, Migliavacca R. 2016. Emergence of *Escherichia coli* sequence type 131 (ST131) and ST3948 with KPC-2, KPC-3 and KPC-8 carbapenemases from a long-term care and rehabilitation facility (LTCRF). *Adv Exp Med Biol* 901:77–89. [https://doi.org/10.1007/5584\\_2015\\_5017](https://doi.org/10.1007/5584_2015_5017)
  67. Munoz-Price LS, Reeme AE, Buchan BW, Mettuss RT, Mustapha MM, Van Tyne D, Shields RK, Doi Y. 2019. Patient-to-patient transmission of *Klebsiella pneumoniae* carbapenemase variants with reduced ceftazidime-avibactam susceptibility. *Antimicrob Agents Chemother* 63:e00955-19. <https://doi.org/10.1128/AAC.00955-19>
  68. Mueller L, Masseron A, Prod'Hom G, Galperine T, Greub G, Poirel L, Nordmann P. 2019. Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity. *Antimicrob Agents Chemother* 63:e01111-19. <https://doi.org/10.1128/AAC.01111-19>
  69. Poirel L, Vuillemin X, Juhas M, Masseron A, Bechtel-Grosch U, Tiziani S, Mancini S, Nordmann P. 2020. KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity. *Antimicrob Agents Chemother* 64:e00321-20. <https://doi.org/10.1128/AAC.00321-20>
  70. Niu S, Chavda KD, Wei J, Zou C, Marshall SH, Dhawan P, Wang D, Bonomo RA, Kreiswirth BN, Chen L. 2020. A ceftazidime-avibactam-resistant and carbapenem-susceptible *Klebsiella pneumoniae* strain harboring *bla*<sub>KPC-14</sub>: Isolated in New York City. *mSphere* 5 (4):e00775-20. <https://doi.org/10.1128/mSphere.00775-20>
  71. Queslati S, Iorga BI, Tilili L, Exilie C, Zavala A, Dortet L, Jousset AB, Bernabeu S, Bonnin RA, Naas T. 2019. Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. *J Antimicrob Chemother* 74:2239–2246. <https://doi.org/10.1093/jac/dkz209>
  72. Sun L, Chen W, Li H, Li L, Zou X, Zhao J, Lu B, Li B, Wang C, Li H, Liu Y, Cao B. 2020. Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing *Klebsiella pneumoniae* ST11 clone background. *J Antimicrob Chemother* 75:3072–3074. <https://doi.org/10.1093/jac/dkaa241>
  73. Di Pilato V, Aiezza N, Viaggi V, Antonelli A, Principe L, Giani T, Luzzaro F, Rossolini GM. 2020. KPC-53, a KPC-3 variant of clinical origin associated with reduced susceptibility to ceftazidime-avibactam. *Antimicrob Agents Chemother* 65:e01429-20. <https://doi.org/10.1128/AAC.01429-20>
  74. Poirel L, Sadek M, Kusaksizoglu A, Nordmann P. 2022. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. *Eur J Clin Microbiol Infect Dis* 41:677–680. <https://doi.org/10.1007/s10096-021-04397-x>
  75. Qin J, Feng Y, Lü X, Zong Z. 2021. KPC-12 with a L169m substitution in the Ω loop has reduced carbapenemase activity. *Eur J Clin Microbiol Infect Dis* 40:1761–1766. <https://doi.org/10.1007/s10096-021-04198-2>
  76. Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M. 2019. Genomic characterization of a KPC-23-producing *Klebsiella pneumoniae* ST258 clinical isolate resistant to ceftazidime-avibactam. *Clin Microbiol Infect* 25:763. <https://doi.org/10.1016/j.cmi.2019.03.011>
  77. Gaibani P, Ambretti S, Campoli C, Viale P, Re MC. 2020. Genomic characterization of a *Klebsiella pneumoniae* ST1519 resistant to

- ceftazidime/avibactam carrying a novel KPC variant (KPC-36). *Int J Antimicrob Agents* 55:105816. <https://doi.org/10.1016/j.ijantimicag.2019.09.020>
78. Yoon E-J, Choi YJ, Park SH, Shin JH, Park SG, Choi JR, Jeong SH. 2020. A novel KPC variant KPC-55 in *Klebsiella pneumoniae* ST307 of reinforced meropenem-hydrolyzing activity. *Front Microbiol* 11:561317. <https://doi.org/10.3389/fmicb.2020.561317>
  79. Mendes G, Ramalho JF, Bruschy-Fonseca A, Lito L, Duarte A, Melo-Cristino J, Caneiras C. 2022. First description of ceftazidime/avibactam resistance in a ST13 KPC-70-producing *Klebsiella pneumoniae* strain from Portugal. *Antibiotics (Basel)* 11:167. <https://doi.org/10.3390/antibiotics11020167>
  80. Li X, Quan J, Ke H, Wu W, Feng Y, Yu Y, Jiang Y. 2021. Emergence of a KPC variant conferring resistance to ceftazidime-avibactam in a widespread ST11 carbapenem-resistant *Klebsiella pneumoniae* clone in China. *Front Microbiol* 12:724272. <https://doi.org/10.3389/fmicb.2021.724272>
  81. Guzmán-Puche J, Pérez-Nadales E, Pérez-Vázquez M, Causse M, Gracia-Ahufinger I, Mendez-Natera A, Allalou-Ruiz Y, Elías C, Oteo-Iglesias J, Torre-Cisneros J, Martínez-Martínez L. 2022. *In vivo* selection of KPC-94 and KPC-95 in *Klebsiella pneumoniae* isolates from patients treated with ceftazidime/avibactam. *Int J Antimicrob Agents* 59:106524. <https://doi.org/10.1016/j.ijantimicag.2022.106524>
  82. Shen S, Tang C, Ding L, Han R, Yin D, Yang W, Guo Y, Hu F, Bradford PA. 2022. Identification of KPC-112 from an ST15 *Klebsiella pneumoniae* strain conferring resistance to ceftazidime-avibactam. *mSphere* 7:e0048722. <https://doi.org/10.1128/msphere.00487-22>
  83. Nicola F, Cejas D, González-Espinosa F, Relloso S, Herrera F, Bonvehí P, Smayevsky J, Figueroa-Espinosa R, Gutkind G, Radice M, Rosato AE. 2022. Outbreak of *Klebsiella pneumoniae* ST11 resistant to ceftazidime-avibactam producing KPC-31 and the novel variant KPC-115 during COVID-19 pandemic in Argentina. *Microbiol Spectr* 10:e0373322. <https://doi.org/10.1128/spectrum.03733-22>
  84. Gaibani P, Amadesi S, Lazzarotto T, Ambretti S. 2022. Genome characterization of a *Klebsiella pneumoniae* co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient. *J Glob Antimicrob Resist* 30:262–264. <https://doi.org/10.1016/j.jgar.2022.06.021>
  85. Wang L, Shen W, Zhang R, Cai J. 2022. Identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in *Citrobacter koseri* following ceftazidime-avibactam treatment. *Front Microbiol* 13:930777. <https://doi.org/10.3389/fmicb.2022.930777>
  86. Performance standards for antimicrobial susceptibility testing. 2021. 31st ed. CLSI supplement M100
  87. Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. 2008. Simple disk-based method for detection of *Klebsiella pneumoniae* carbapenemase-type beta-lactamase by use of a boronic acid compound. *J Clin Microbiol* 46:4083–4086. <https://doi.org/10.1128/JCM.01408-08>
  88. Lau AF, Wang H, Weingarten RA, Drake SK, Suffredini AF, Garfield MK, Chen Y, Gucek M, Youn J-H, Stock F, Tso H, DeLeo J, Cimino JJ, Frank KM, Dekker JP. 2014. A rapid matrix-assisted laser desorption/ionization-time of flight mass spectrometry-based method for single-plasmid tracking in an outbreak of carbapenem-resistant enterobacteriaceae. *J Clin Microbiol* 52:2804–2812. <https://doi.org/10.1128/JCM.00694-14>
  89. Hopkins KL, Meunier D, Naas T, Volland H, Woodford N. 2018. Evaluation of the NG-test CARBA 5 multiplex immunochromatographic assay for the detection of KPC, OXA-48-like, NDM, VIM and IMP carbapenemases. *J Antimicrob Chemother* 73:3523–3526. <https://doi.org/10.1093/jac/dky342>
  90. Tato M, Ruiz-Garbajosa P, Traczewski M, Dodgson A, McEwan A, Humphries R, Hindler J, Veltman J, Wang H, Cantón R. 2016. Multisite evaluation of cepheid Xpert carba-R assay for detection of carbapenemase-producing organisms in rectal swabs. *J Clin Microbiol* 54:1814–1819. <https://doi.org/10.1128/JCM.00341-16>
  91. De Angelis G, Grossi A, Menchinelli G, Boccia S, Sanguinetti M, Posteraro B. 2020. Rapid molecular tests for detection of antimicrobial resistance determinants in gram-negative organisms from positive blood cultures: a systematic review and meta-analysis. *Clin Microbiol Infect* 26:271–280. <https://doi.org/10.1016/j.cmi.2019.11.009>
  92. Moore NM, Cantón R, Carretto E, Peterson LR, Sautter RL, Traczewski MM, Carba-R Study Team. 2017. Rapid identification of five classes of Carbapenem resistance genes directly from Rectal Swabs by use of the Xpert Carba-R assay. *J Clin Microbiol* 55:2268–2275. <https://doi.org/10.1128/JCM.00137-17>
  93. Cunningham SA, Limbago B, Traczewski M, Anderson K, Hackel M, Hindler J, Sahn D, Alyanak E, Lawsin A, Gulvik CA, de Man TJB, Mandrekar JN, Schuetz AN, Jenkins S, Humphries R, Palavecino E, Vasoo S, Patel R. 2017. Multicenter performance assessment of carba NP test. *J Clin Microbiol* 55:1954–1960. <https://doi.org/10.1128/JCM.00244-17>
  94. Lutgring JD, Zhu W, de Man TJB, Avillan JJ, Anderson KF, Lonsway DR, Rowe LA, Batra D, Rasheed JK, Limbago BM. 2018. Phenotypic and genotypic characterization of enterobacteriaceae producing Oxacillinase-48-like carbapenemases, United States. *Emerg Infect Dis* 24:700–709. <https://doi.org/10.3201/eid2404.171377>
  95. Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso WB, Bobenchik AM, Lockett ZC, Charnot-Katsikas A, Ferraro MJ, Thomson RB, Jenkins SG, Limbago BM, Das S. 2017. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among enterobacteriaceae. *J Clin Microbiol* 55:2321–2333. <https://doi.org/10.1128/JCM.00193-17>
  96. Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, Das S, Satlin MJ, Jenkins SG, Westblade LF. 2019. EDTA-modified carbapenem inactivation method: a phenotypic method for detecting metallo- $\beta$ -lactamase-producing enterobacteriaceae. *J Clin Microbiol* 57:e01757-18. <https://doi.org/10.1128/JCM.01757-18>
  97. Tsakris A, Poulou A, Pournaras S, Voulgari E, Vrioni G, Themeli-Digalaki K, Petropoulou D, Sofianou D. 2010. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in enterobacteriaceae clinical isolates. *J Antimicrob Chemother* 65:1664–1671. <https://doi.org/10.1093/jac/dkq210>
  98. Huang Y-T, Kuo Y-W, Lee N-Y, Tien N, Liao C-H, Teng L-J, Ko W-C, Hsueh P-R, SMART study group. 2022. Evaluating NG-test CARBA 5 multiplex immunochromatographic and cepheid Xpert CARBA-R assays among carbapenem-resistant *Enterobacterales* isolates associated with bloodstream infection. *Microbiol Spectr* 10:e0172821. <https://doi.org/10.1128/spectrum.01728-21>
  99. Hernández-García M, Castillo-Polo JA, Cordero DG, Pérez-Viso B, García-Castillo M, Saez de la Fuente J, Morosini MI, Cantón R, Ruiz-Garbajosa P. 2022. Impact of ceftazidime-avibactam treatment in the emergence of novel KPC variants in the ST307-*Klebsiella pneumoniae* high-risk clone and consequences for their routine detection. *J Clin Microbiol* 60:e0224521. <https://doi.org/10.1128/jcm.02245-21>
  100. Gu D, Yan Z, Cai C, Li J, Zhang Y, Wu Y, Yang J, Huang Y, Zhang R, Wu Y. 2023. Comparison of the NG-test carba 5, colloidal gold immunoassay (CGI) test, and Xpert carba-R for the rapid detection of carbapenemases in carbapenemase-producing organisms. *Antibiotics (Basel)* 12:300. <https://doi.org/10.3390/antibiotics12020300>
  101. Lee YR, Baker NT. 2018. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant enterobacteriaceae. *Eur J Clin Microbiol Infect Dis* 37:1411–1419. <https://doi.org/10.1007/s10096-018-3260-4>
  102. Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. 2020. Meropenem-vaborbactam activity against carbapenem-resistant *Enterobacterales* isolates collected in U.S hospitals during. *Antimicrob Agents Chemother* 64:e01951-19. <https://doi.org/10.1128/AAC.01951-19>
  103. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. 2020. New  $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations. *Clin Microbiol Rev* 34:e00115-20. <https://doi.org/10.1128/CMR.00115-20>
  104. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. 2015. Activity of meropenem combined with RPX7009, a novel  $\beta$ -lactamase inhibitor, against gram-negative clinical isolates in New York City. *Antimicrob Agents Chemother* 59:4856–4860. <https://doi.org/10.1128/AAC.00843-15>
  105. Castanheira M, Huband MD, Mendes RE, Flamm RK. 2017. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae. *Antimicrob Agents Chemother* 61:e00567-17. <https://doi.org/10.1128/AAC.00567-17>
  106. Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. 2018. *In vitro* activity of meropenem/vaborbactam and characterisation of



- carbapenem resistance mechanisms among carbapenem-resistant enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. *Int J Antimicrob Agents* 52:144–150. <https://doi.org/10.1016/j.ijantimicag.2018.02.021>
107. Jousset AB, Oueslati S, Emeraud C, Bonnin RA, Dortet L, Iorga BI, Naas T. 2021. KPC-39-mediated resistance to ceftazidime-avibactam in a *Klebsiella pneumoniae* ST307 clinical isolate. *Antimicrob Agents Chemother* 65:e0116021. <https://doi.org/10.1128/AAC.01160-21>
  108. Bongiorno D, Bivona DA, Cicino C, Treçarichi EM, Russo A, Marascio N, Mezzatesta ML, Musso N, Privitera GF, Quirino A, Scarlata GGM, Matera G, Torti C, Stefani S. 2022. Omic insights into various ceftazidime-avibactam-resistant *Klebsiella pneumoniae* isolates from two Southern Italian regions. *Front Cell Infect Microbiol* 12:1010979. <https://doi.org/10.3389/fcimb.2022.1010979>
  109. Castillo-Polo JA, Hernández-García M, Morosini MI, Pérez-Viso B, Soriano C, De Pablo R, Cantón R, Ruiz-Garbajosa P. 2023. Outbreak by KPC-62-producing ST307 *Klebsiella pneumoniae* isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain. *J Antimicrob Chemother* 78:1259–1264. <https://doi.org/10.1093/jac/dkad086>
  110. Mangion IK, Ruck RT, Rivera N, Huffman MA, Shevlin M. 2011. A concise synthesis of a  $\beta$ -lactamase inhibitor. *Org Lett* 13:5480–5483. <https://doi.org/10.1021/ol202195n>
  111. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuk A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2018. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem–lactamase inhibitor combinations. *Drugs* 78:65–98. <https://doi.org/10.1007/s40265-017-0851-9>
  112. Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF. 2017. *in vitro* activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program). *Antimicrob Agents Chemother* 61:e02209-16. <https://doi.org/10.1128/AAC.02209-16>
  113. Papp-Wallace KM, Barnes MD, Alsop J, Taracila MA, Bethel CR, Becka SA, van Duin D, Kreiswirth BN, Kaye KS, Bonomo RA. 2018. Relebactam is a potent inhibitor of the KPC-2  $\beta$ -lactamase and restores imipenem susceptibility in KPC-producing enterobacteriaceae. *Antimicrob Agents Chemother* 62:e00174-18. <https://doi.org/10.1128/AAC.00174-18>
  114. Carpenter J, Neidig N, Campbell A, Thornsberrry T, Truex T, Fortney T, Zhang Y, Bush K. 2019. Activity of imipenem/relebactam against carbapenemase-producing enterobacteriaceae with high colistin resistance. *J Antimicrob Chemother* 74:3260–3263. <https://doi.org/10.1093/jac/dkz354>
  115. Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant enterobacteriaceae. *Antimicrob Agents Chemother* 61:e00642-17. <https://doi.org/10.1128/AAC.00642-17>
  116. Sader HS, Carvalhaes CG, Arends SJR, Castanheira M, Mendes RE. 2021. Aztreonam/avibactam activity against clinical isolates of enterobacteriales collected in Europe, Asia and Latin America in 2019. *J Antimicrob Chemother* 76:659–666. <https://doi.org/10.1093/jac/dkaa504>
  117. Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, Yang Y, Wu S, Yin D, Zhu D, Hu F, Lamichhane G. 2022. *In vitro* activity of new  $\beta$ -lactam- $\beta$ -lactamase inhibitor combinations and comparators against clinical isolates of gram-negative bacilli: results from the China antimicrobial surveillance network (CHINET) in 2019. *Microbiol Spectr* 10:e0185422. <https://doi.org/10.1128/spectrum.01854-22>
  118. McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. 2013. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. *Int J Antimicrob Agents* 41:463–467. <https://doi.org/10.1016/j.ijantimicag.2013.01.020>
  119. Doi Y. 2019. Treatment options for carbapenem-resistant gram-negative bacterial infections. *Clin Infect Dis* 69:S565–S575. <https://doi.org/10.1093/cid/ciz830>
  120. Huang J, Yi M, Yuan Y, Xia P, Yang B, Liao J, Dang Z, Luo S, Xia Y. 2022. Emergence of a fatal ST11-Kl64 tigecycline-resistant hypervirulent *Klebsiella pneumoniae* clone cocarrying *bla<sub>NDM</sub>* and *bla<sub>KPC</sub>* in plasmids. *Microbiol Spectr* 10:e0253922. <https://doi.org/10.1128/spectrum.02539-22>
  121. Xu Q, Sheng Z, Hao M, Jiang J, Ye M, Chen Y, Xu X, Guo Q, Wang M. 2021. RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in *Klebsiella pneumoniae*. *Int J Antimicrob Agents* 57:106251. <https://doi.org/10.1016/j.ijantimicag.2020.106251>
  122. Linkevicius R, Sandegren L, Andersson DI. 2016. Potential of tetracycline resistance proteins to evolve tigecycline resistance. *Antimicrob Agents Chemother* 60:789–796. <https://doi.org/10.1128/AAC.02465-15>
  123. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, Ghafouri Z, Maleki F. 2021. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur J Clin Microbiol Infect Dis* 41:1003–1022. <https://doi.org/10.1007/s10096-020-04121-1>
  124. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. *Lancet Infect Dis* 6:589–601. [https://doi.org/10.1016/S1473-3099\(06\)70580-1](https://doi.org/10.1016/S1473-3099(06)70580-1)
  125. Nang SC, Azad MAK, Velkov T, Zhou QT, Li J. 2021. Rescuing the last-line polymyxins: achievements and challenges. *Pharmacol Rev* 73:679–728. <https://doi.org/10.1124/pharmrev.120.000020>
  126. Yang Y, Guo Y, Yin D, Zheng Y, Wu S, Zhu D, Hu F. 2020. *in vitro* activity of cefepime-zidebactam, ceftazidime-avibactam, and other comparators against clinical isolates of enterobacterales, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*: results from China antimicrobial surveillance network (CHINET) in 2018. *Antimicrob Agents Chemother* 65:e01726-20. <https://doi.org/10.1128/AAC.01726-20>
  127. Tian Y, Zhang Q, Wen L, Chen J. 2021. Combined effect of polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant *Klebsiella pneumoniae*. *Microbiol Spectr* 9:e0015221. <https://doi.org/10.1128/Spectrum.00152-21>
  128. Chen X, Li P, Sun Z, Xu X, Jiang J, Su J. 2022. Insertion sequence mediating mrgB disruption is the major mechanism of polymyxin resistance in carbapenem-resistant *Klebsiella pneumoniae* isolates from China. *J Glob Antimicrob Resist* 30:357–362. <https://doi.org/10.1016/j.jgar.2022.07.002>
  129. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161–168. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7)

## AUTHOR BIOS

**Li Ding** received her Master's degree in Clinical Laboratory Diagnostics from Huashan Hospital, Fudan University, Shanghai, China in 2020. She is currently working in the Department of Clinical Microbiology at the Institute of Antibiotics, Huashan Hospital, Fudan University, mainly involved in bacterial resistance monitoring and in vitro pharmacodynamic evaluation of new antimicrobial agents. She is very interested in the mechanism of carbapenem-resistant Enterobacteriaceae and has published several articles in international peer-reviewed journals.



**Siquan Shen** received his Master's degree in Clinical Laboratory Diagnostics from Huashan Hospital, Fudan University, Shanghai, China in 2023. He is currently working in the Department of Clinical Microbiology, Institute of Antibiotics, Huashan Hospital. His main research interests include various aspects of carbapenemase-mediated resistance in enterobacterial species. He is also involved in projects on bacterial resistance monitoring research and in vitro pharmacodynamics of new antibiotics. Many related articles have been published in internationally renowned journals.



**Jing Chen** received his Master's degree from Southwest University in Chongqing, China in 2010. In the same year, he joined the BGI Microbial Platform, demonstrating a long-term commitment to the development of microbial NGS data. Over the years, he has been actively involved in numerous projects under the State High-Tech Development Plan (863 Programme) and the National Natural Science Foundation of China. Since 2019, he has been leading the development of bioinformatics-related algorithms and software at Hangzhou Matrix Biotechnology Co., Ltd.



**Zhen Tian** graduated from Fujian Agriculture and Forestry University, China with a Master's degree in Ecology in 2021. After graduation, he joined Hangzhou Matrix Biotechnology Co., Ltd. as a bioinformatics analyst, where he was responsible for the development of R-related processes. He has a strong interest in bioinformatics and next-generation sequencing (NGS), with a commitment to using bioinformatics tools to identify sources of infection.



**Qingyu Shi** received her Master's degree in Clinical Laboratory Diagnostics from Huashan Hospital of Fudan University in 2021, and went on to study for her PhD. She mainly researches antibiotic resistance mechanisms of enterobacteria, especially those mediated by carbapenemase. She is also actively involved in antimicrobial surveillance and in vitro pharmacodynamics of new antibiotics. Several related articles have been published in internationally renowned journals.



**Renru Han** works in clinical microbiology at the Institute of Antibiotics, Huashan Hospital, Fudan University. She works on bacterial resistance monitoring research and in vitro pharmacodynamics of new antibiotics. She has been focusing on the resistance mechanisms of carbapenem-resistant Enterobacteriales for several years. Some related articles have been published in *Journal of Antimicrobial Chemotherapy*, *Microbiology Spectrum*, *Frontiers in Microbiology*, etc.



**Yan Guo** works in clinical microbiology at the Institute of Antibiotics, Huashan Hospital, Fudan University. She has focused on bacterial resistance surveillance research for nearly twenty years. She was a visiting scholar in Yohei Doi's lab at the University of Pittsburgh from 2016 to 2017. Another part of her work is in vitro pharmacodynamics of new antibiotics. Some related articles have been published in *JAC*, *AAC*, *EJCMID*, etc. She is skilled in antimicrobial susceptibility testing and is interested in research on bacterial resistance mechanisms, especially in VRE.



**Fupin Hu** is a clinical microbiologist at Huashan Hospital, Fudan University. He received his PhD in infectious diseases in 2010 and is now deputy director of the Institute of Antibiotics. Dr Hu has long been involved in research, mainly focusing on bacterial resistance surveillance and new mechanisms of drug resistance. He is one of the leaders of the China Antimicrobial Surveillance Network (CHINET, [www.chinets.com](http://www.chinets.com)). His main research interests include methodological standardisation of antimicrobial susceptibility testing, development of breakpoint for antimicrobial susceptibility testing of new antibacterial agents, evaluation of in vitro activities of new antimicrobial agents, mechanisms of transmission of bacterial resistance to carbapenems (especially mutation of KPC enzyme gene) and risk factors for infection.

